Stem cells in clinical practice: applications and warnings by Lodi, Daniele et al.
REVIEW Open Access
Stem cells in clinical practice: applications and
warnings
Daniele Lodi
1, Tommaso Iannitti
2*, Beniamino Palmieri
3
Abstract
Stem cells are a relevant source of information about cellular differentiation, molecular processes and tissue
homeostasis, but also one of the most putative biological tools to treat degenerative diseases. This review focuses
on human stem cells clinical and experimental applications. Our aim is to take a correct view of the available stem
cell subtypes and their rational use in the medical area, with a specific focus on their therapeutic benefits and side
effects. We have reviewed the main clinical trials dividing them basing on their clinical applications, and taking into
account the ethical issue associated with the stem cell therapy.
Methods: We have searched Pubmed/Medline for clinical trials, involving the use of human stem cells, using the
key words “stem cells” combined with the key words “transplantation”, “pathology”, “guidelines”, “properties” and
“risks”. All the relevant clinical trials have been included. The results have been divided into different categories,
basing on the way stem cells have been employed in different pathological conditions.
Introduction
The word “stemness” defines a series of properties
which distinguish a heterogeneous variety of cell popula-
tion. However, in the absence of a current consensus on
a gold standard protocol to isolate and identify SCs, the
definition of “stemness” is in a continuous evolution
[1-3].
Biologically, stem cells (SCs) are characterized by self-
renewability [4], that is the ability not only to divide
themselves rapidly and continuously, but also to create
new SCs and progenitors more differentiated than the
mother cells. The asymmetric mitosis is the process
which permits to obtain two intrinsically different
daughter cells. A cell polarizes itself, so that cell-fate
determinant molecules are specifically localized on one
side. After that, the mitotic spindle aligns itself perpen-
dicularly to the cell axis polarity. At the end of the pro-
cess two different cells are obtained [5-7].
SCs show high plasticity, i.e. the complex ability to
cross lineage barriers and adopt the expression profile
and functional phenotypes of the cells that are typical
of other tissues. The plasticity can be explained by
transdifferentiation (direct or indirect) and fusion.
Transdifferentiation is the acquisition of the identity of
ad i f f e r e n tp h e n o t y p et h r o u g ht h ee x p r e s s i o no ft h e
gene pattern of other tissue (direct) or through the
achievement of a more primitive state and the succes-
sive differentiation to another cell type (indirect or de-
differentiation). By fusion with a cell of another tissue, a
cell can express a gene and acquire a phenotypic ele-
ment of another parenchyma [3].
SCs morphology is usually simpler than that one of
the committed cells of the same lineage. It has often got
a circular shape depending on its tissue lineage and a
low ratio cytoplasm/nucleus dimension, i.e. a sign of
synthetic activity. Several specifics markers of general or
lineage “stemness” have been described but some, such
as alkaline phosphatase, are common to many cell types
[1,8-11].
From the physiological point of view, adult stem cells
(ASCs) maintain the tissue homeostasis as they are
already partially committed. ASCs usually differentiate
in a restricted range of progenitors and terminal cells to
replace local parenchyma (there is evidence that trans-
differentiation is involved in injury repair in other dis-
tricts [12], damaged cells or sustaining cellular turn over
[13]). SCs derived from early human embryos (Embryo-
nic stem cells (ESCs)), instead, are pluripotent and can
generate all committed cell types [14,15]. Fetal stem
cells (FSCs) derive from the placenta, membranes,
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any medium, provided the original work is properly cited.amniotic fluid or fetal tissues. FSCs are higher in num-
ber, expansion potential and differentiation abilities if
compared with SCs from adult tissues [16]. Naturally,
the migration, differentiation and growth are mediated
by the tissue, degree of injury and SCs involved.
Damaged tissue releases factors that induce SCs homing.
The tissue, intended as stromal cells, extracellular
matrix, circulating growth and differentiating factors,
determines a gene activation and a functional reaction
on SCs, such as moving in a specific district, differen-
tiating in a particular cell type or resting in specific
niches. These factors can alter the gene expression pat-
tern in SCs when they reside in a new tissue [17].
Scientific research has been working to understand
and to indentify the molecular processes and cellular
cross-talking that involve SCs. Only with a deep knowl-
edge of the pathophysiological mechanism involving
S C s ,w em i g h tb ea b l et or e p roduce them in a labora-
tory and apply the results obtained in the treatment of
degenerative pathologies, i.e. neurological disorder such
as Parkinson’s disease (PD), Alzheimer’s disease (AD),
Huntington’s disease, multiple sclerosis [18], musculos-
keletal disorder [19], diabetes [20], eye disorder [21],
autoimmune diseases [22], liver cirrhosis [23], lung dis-
ease [24] and cancer [25].
In spite of the initial enthusiasm for their potential
therapeutic application, SCs are associated with several
burdens that can be observed in clinical practice. Firstly,
self-renewal and plasticity are properties which also
characterize cancer cells and the hypothesis to lose con-
trol on transplanted SCs, preparing a fertile ground for
tumor development, is a dangerous and unacceptable
side effect [26,27]. Secondly, in case of allogenic SCs
graft, several cases of immunorejection or graft versus
host disease [28] are reported, with a necessary immu-
nosuppressive treatment to avoid immune response
against the transplant and the consequent risk of infec-
tions. Finally, to succeed in ESCs cultures, it is necessary
to manipulate and to reproduce embryos for scientific
use, but the Catholic World identifies this stage of the
human development with birth and attributes embryos
the same rights [29].
Stem Cells Types
SCs are commonly defined as cells capable of self-renewal
through replication and differentiating into specific
lineages. Depending on “differentiating power”,S C sa r e
divided into several groups. The cells, deriving from an
early progeny of the zygote up to the eight cell stage of the
morula, are defined as “totipotent”, due to their ability to
form an entire organism [30]. The “pluripotent” cells, such
as ESCs, can generate the tissues of all embryonic germ
layers, i.e. endoderm, mesoderm, and ectoderm, while
“multipotent” cells, such as ASCs, are capable of yielding a
more restricted subset of cell lineages. Another type of
SCs classification is based on the developmental stage
from which they are obtained, i.e. embryonic origin (ESCs)
or postnatal derivation (ASCs) [3].
Embryo-derived stem cells
A zygote is the initial cell originating when a new
organism is produced by means of sexual reproduction.
Zygotes are usually produced by a fertilization event
between two haploid cells, i.e. an ovum from a female
and a sperm cell from a male, which combine to form
the single diploid cell [31].
The blastocyst is the preimplantation stage in embryos
aged one week approximately. The blastocyst is a cave
structure compound made by the trophectoderm, an
outer layer of cells filling cavity fluid and an inner cell
mass (ICM), i.e. a cluster of cells on the interior layer
[32-35].
Embryonic cells (EC, epiblast) are contained in the
ICM and generate the organism, whereas the surround-
ing trophoblast cells contribute to the placental chorion.
Traditionally, ECs are capable of a self-renewal and dif-
ferentiation into cells of all tissue lineages [15], but not
into embryonic annexes as such zygote. ECs can be cul-
tured and ESCs can be maintained for a long time (1-2
years with cell division every 36-48 hours) in an undiffer-
entiated phenotype [10,33,36] and which unchanged
properties. ECs can be isolated by physical micro dissec-
tion or by complement-mediated immune dissection.
ECs are preserved through fast freeze or vitrification
techniques to avoid an early natural differentiation
[37-39]. Culturing ESCs requires a special care, in fact,
under SCs, a feeder layer of primary murine fibroblast is
seeded in a permanent replication block that sustains
continuously undifferentiated ESCs [14]. ESCs are main-
tained for a long time in culture to obtain a large pool of
undifferentiated SCs for therapeutic and research appli-
cations. In contrast, somatic cells and mesenchimal stem
cells (MSCs) have finite replicative lifespan after which
they can no longer divide and are said to have reached a
proliferative senescence [40]. The replicative lifespan of
cells depends on the cell type, donor’s species, and
donor’s age, but it is directly related to telomerase activity
[41-44]. Telomerase is an enzyme which adds specific
short sequences to chromosomes ends, aiming at preser-
ving chromosome length and supporting the ongoing cell
division [42]. Telomerase activity is decreased by com-
mitting and, as a result, it is characteristically high in
ESCs, intermediate in haematopoietic stem cells (HSCs),
and variable, or even absent, in somatic cells [3,42].
Fetal stem cells
FSCs are multipotent cells with the same functional
properties of ASCs, but they locate in the fetal tissue
Lodi et al. Journal of Experimental & Clinical Cancer Research 2011, 30:9
http://www.jeccr.com/content/30/1/9
Page 2 of 20and embryonic annexes. Indeed, further analyses are
necessary to investigate whether ASCs are the same pre-
sent in the tissue. FSCs have been subdivided into hae-
mopoietic ones, located in blood, liver, bone marrow
(BM), mesenchymal ones located in blood, liver, BM,
lung, kidney and pancreas, endothelial ones found in
BM and placenta, epithelial ones located in liver and
pancreas and neural ones located in brain and spinal
cord [45]. Obviously, the only source of FSCs, relatively
feasible and safe for fetus, is fetal blood [46]. Nowadays
a routine procedure for fetal diagnosis and therapy,
which are the most diffuse techniques to harvest FSCs,
is ultrasound guided accession to fetal circulation [45].
Adult stem cells
ASCs are partially committed SCs localized in specific
stromal niches. ASCs can be obtained from the meso-
dermal tissues such as BM [1,47], muscle [48], adipose
tissue [49], synovium [50] and periosteum [51]. SCs
have been also isolated from the tissues of endodermal
lineages such as intestine [52] and from the ectodermal
tissues including skin [53], deciduous teeth [54] and
nerve tissue [8,9,55,56]. ASCs originate during ontogen-
esis and remain in a marginal area in a quiescent state
as the local stimuli induce their cycle recruitment and
migration. In fact, niche microenvironment, with physi-
cal contact and chemical dialogue among SCs, stromal
cells and matrix, induce ASCs differentiation and self-
renewal [57,58].
Probably, for documented plasticity and easy extrac-
tion, several ASCs types, such as HSCs, adipose tissue-
derived stromal cells (ADSCs) and derived MSCs, have
had and have a historical importance. HSCs are well
characterized cells of mesodermal origin deriving preva-
lently from BM, in particular near endosteal bone sur-
face and sinusoidal endothelium and from peripheral
blood. Traditionally HSCs generate all mature blood cell
types of the hematolymphatic system including neutro-
phils, monocytes/macrophages, basophils, eosinophils,
erythrocytes, platelets, mast cells, dendritic cells, and B
and T lymphocytes. More recently, HSCs have shown to
d i s p l a yr e m a r k a b l ep l a s t i c i t y and can apparently differ-
entiate into several non-hemolymphatic tissue lineages
[3]. The identification and isolation of HSCs is possible
with immune capture of CD34, a surface protein that
distinguishes SCs from other hematopoietic cells [59].
HSCs are at the base of BM transplant procedures, i.e.
myeloablation or adiuvant therapy where HSCs are
infused in the recipient [60].
MSCs originally derive from BM, [1,8,47] but they have
been isolated from other tissues, such as adipose tissue,
periosteum, synovial membrane, synovial fluid (SF), mus-
cle, dermis, deciduous teeth, pericytes, trabecular bone,
infrapatellar fat pad, and articular cartilage [1,19,47,61-68].
They are generally restricted to forming only mesodermal-
specific cell types such as adipocytes, osteoblasts, myocytes
and chondrocytes, but several MSCs are able to differenti-
ate in cells of the three embryonic germ layers [69]. Sev-
eral of these studies report the differentiation of MSCs
into various tissue lineages in vitro and the repair or
“engraftment” of the damaged organs in vivo, such as
bone tissue repair and immune system reconstruction, but
they are even able to differentiate in endothelial cells and
contribute to revascularization of the ischemic tissue
[3,70,71]. In particular, recent studies show that cultured
MSCs secrete various bioactive molecules which have got
anti-apoptotic, immunomodulatory, angiogenic, anti-
scarring and chemo-attractant properties, providing a
basis for their use as tools to create local regenerative
environments in vivo [72].
Umbilical cord stem cells
In the umbilical cord, we can find two types of SC
sources, i.e. the umbilical cord epithelium (UCE),
derived from the amniotic membrane epithelium and
the umbilical cord blood (UCB) [73]. Although its gen-
eral architecture significantly differs from the mamma-
lian epidermis, UCE expresses a cytokeratin pattern
similar to human epidermis [74,75]. UCE is able to form
a stratified epithelium when seeded on fibroblast popu-
lated collagen gels [76,77]. It has been demonstrated
that UCE is an important source of the human primary
keratinocytes and it is able to recreate the epidermis for
dermatological application [78]. In UCB we can find two
different types of SCs, i.e. hematopoietic (UC-HS) and
mesenchymal (UC-MS). Although UCB SCs are biologi-
cally analogous to their adult counterpart, it has been
pointed out that UCB cells are characterized by a higher
immunological tolerance than their adult counterpart
[79]. Indeed UC-MS can produce cytokines which facili-
tate grafting in the donor, in vitro SC survival and it is
more efficient than BM MSC graft [80].
Risks And Obstacles To Stem Cells Application In
Clinical Practice
Risks
SC graft induces therapeutic and side effects. A specific
evaluation of the side effects is needed to decide if a
cure can be adopted in medical practice. Indeed, scienti-
fic research has to outline the severity of undesired
effects, their frequency in treated subjects and the possi-
bility to avoid, reduce or abate them. The major limita-
tions to the success of HSC transplantation (HSCT) are
respiratory complications and graft versus host disease.
Lung dysfunction occurs in up to 50% of the subjects
after HSCT, and pulmonary complications are among
the most common causes of morbidity and mortality
after this procedure.
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cess involving both alloimmunologic and nonalloimmu-
nologic reactions as the heterogeneous histopathologic
findings and clinical course suggest. Since the occur-
rence of OB has been closely associated with GVHD, it
has been hypothesized that OB is mediated, partially, by
alloimmunologic injury to host bronchiolar epithelial
cells [81-83]. Usually, OB develops as a late complica-
t i o n ,i . e .a f t e rt h ef i r s t1 0 0d a y s ,o fH S C T .T h eO B
onset is usually 6-12 months post-transplant, with the
clinical seriousness ranging from asymptomatic severity
to a fulminant and fatal one. The pathogenesis of the
disease is believed to primarily involve the interplay
among immune effectors cells that have been recruited
from the lung and cells resident in the pulmonary vas-
cular endothelium and interstitium. This complex pro-
cess results in the loss of type I pulmonary epithelial
cells, a proliferation of type II cells, the recruitment and
proliferation of endothelial cells and the deposition of
the extracellular matrix. In response to the pattern of
injury, cytokines are released from immune effectors
cells and lung cells, i.e. macrophages, alveolar epithelial,
and vascular endothelial cells, and they can stimulate
the fibroblast proliferation and increase the synthesis of
collagen and extracellular matrix proteins. The result is
the large deposition of collagen and granulation tissue
in and around the bronchial structures, with the partial
or complete small airway obliteration. Clinical data sug-
gest that nonalloimmunologic inflammatory conditions,
such as viral infections, recurrent aspiration, and condi-
tioning chemoradiotherapy may also play a role in the
pathogenesis of OB after HSC transplantation [84,85].
Bronchiolitis obliterans organizing pneumonia (BOOP)
is a disorder involving bronchioles, alveolar ducts, and
alveoli, whose lumen becomes filled with buds of granu-
lation tissue, consisting of fibroblasts and an associated
matrix of loose connective tissue. It derives from the
proliferative type, and it generally includes mild inflam-
mation of the bronchiolar walls. In contrast to BO,
there is no prominent bronchiolar wall fibrosis or
bronchiolar distortion [86]. The involvement of an
alloimmunologic reaction can be considered, although
the pathogenesis of BOOP following HSCT is poorly
understood. In animal studies, BOOP develops after a
reovirus infection. A significant role for T cells and
Th1-derived cytokines, including interferon-a, is impli-
cated in the development of disease [87]. Indeed, T-cell
depletion prevents from BO and BOOP after allogeneic
hematopoietic SC transplantation with related donors
[88]. A reported case, following syngeneic BM trans-
plantation, suggests that BOOP is not always the result
of an allogeneic immune response [89]. In other non-
HSCT settings, BOOP has been seen in association with
infection, drugs, radiation therapy, and a number of
connective tissue disorders [90]. It has also been shown
that the 2-year cumulative incidence of late-onset non-
infectious pulmonary complications (LONIPC, including
BO and BOOP) has been 10% in 438 patients under-
going HSCT. Moreover, the survival rate at 5 years has
been significantly worse in affected subjects than in
unaffected ones [91].
Graft versus host disease (GVHD) is a frequent and
lethal complication of HSCT that limits the use of this
important therapy. On the basis of pathophysiology and
appearance, GVHD is classified in acute and chronic
one [92]. Acute GVHD occurs prior to day 100 after
transplant and it consists in an enhanced inflammatory/
immune response, mediated by the competent donor’s
lymphocytes, infused into the recipient, where they react
against an environment perceived as a foreign one. The
process is amplified through the tissue release of mole-
cules which stimulate the donor’s lymphocytes. This
apparently contradictory phenomenon is simply a phy-
siological reaction of the damaged tissue to the disease
which has led to the transplant therapy [93]. Acute
GVHD presents clinical manifestations in the skin, i.e.
maculopapular rash, which can spread throughout the
body, dyskeratosis (in severe cases the skin may blister
and ulcerate) [94], in the gastrointestinal tract, i.e. diar-
rhea, emesis, anorexia, abdominal pain, mucosal ulcera-
tion with bleeding, luminal dilatation [95], and in the
liver, i.e. same liver dysfunction of veno-occlusive dis-
ease, drug toxicity, viral infection, sepsis, or iron over-
load [96]. Chronic GVHD is the major cause of late
non-relapse death following HCT [97]. However,
chronic GVHD pathophysiology is not completely
understood. Probably, thymus atrophy or dysfunction,
which can develop after pharmacological preparation of
transplant, play a major role in chronic GVHD manifes-
tation. This fact leads to a peripheral tolerance decrease
and to an increase in the number of autoreactive T lym-
phocytes. Autoreactive T lymphocytes lead to an inter-
feron gamma mediated increase in the collagen
deposition and fibrosis, a characteristic feature of
chronic GVHD [97,98]. The manifestations of chronic
GVHD are protean and often of an autoimmune nature.
Many districts are involved, i.e. skin with dyspigmenta-
tion, alopecia, poikiloderma, lichen planus-like eruptions
or sclerotic features, nails with nail dystrophy or loss,
the mouth with xerostomia, ulcers, lichen-type features,
restrictions of mouth opening from sclerosis, eyes with
dry eyes, sicca syndrome, cicatricial conjunctivitis, mus-
cles, fascia and joints with fasciitis, myositis, or joint
stiffness from contractures, the female genitalia with
vaginal sclerosis, ulcerations, the gastrointestinal tract
with anorexia, weight loss, esophageal web or structures,
liver with jaundice, transaminitis, lungs with restrictive
or obstructive defects on pulmonary function tests,
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nephrotic syndrome (rare), heart with pericarditis and
bone marrow (thrombocytopenia, anemia, neutropenia)
[92,99,100].
Hepatic veno-occlusive disease (VOD) is another
recurrent complication after SC transplantation. VOD is
a condition in which some of the small hepatic veins are
blocked, in this case, by cells. It is a complication of
high-dose chemotherapy given before a BM transplant
a n di ti sm a r k e db yw e i g h tg a i n ,d u et of l u i dr e t e n t i o n ,
increased liver size, and raised levels of bilirubin in the
blood [101,102]. VOD is more frequent in children
undergoing SC transplantation [103].Two hundred and
forty four HSCTs have been evaluated and it has been
found that VOD had appeared in 11% of them. It has
been identified that risk factors for VOD are age <6.7
years, type of VOD prophylaxis, and busulphan-contain-
ing conditioning regimens [104]. Interesting results have
been obtained in VOD treatment by oral defibrotide
[105] and combination of intravenous heparin, oral glu-
tamine and ursodiol [106].
Obstacles and possible solutions
The compatibility between the recipient and the graft is
the main problem that must be faced off when a medi-
cal group decides to transplant organs, tissues or cells
successfully. In SCT, the immunorejection also repre-
sents an important obstacle. If autogenous cells are
available, immunorejection can be bypassed. In fact,
common clinical practice is to harvest autogenous
MCSs, expand them in culture, avoiding microorganism
contamination, and store the obtained cell population
before implantation [9].
Interestingly, allogenic MCSs transplant, obviously
applied in emergency situations, such as spinal cord
injury or myocardial infarction, demonstrates high suc-
cess rates. A tolerance of allogenic MCSs seems to be
induced by the same grafted cells. Indeed, MCSs inhibit
T cell proliferation and maturation through direct cell-
cell effects and by secretion of soluble factors [107,108].
Allogenous EC transplantation is not immunotolerated
as MSCs graft. Therefore, avoiding the EC immunorejec-
tion, several strategies are being developed. Somatic cell
nuclear transfer (SCNT) is currently the most promising
of them. SCNT consists in the enucleation of the donor’s
oocytes and the renucleation of them with nuclei taken
from the patient’s somatic cells. The created cells are tol-
erated because they express major histocompatability
complex (MHC) of the recipient. The disadvantages of
SCNT include the creation and destruction of embryos
and the current inability to apply the technology in auto-
immune diseases [109]. In order to avoid autoimmune
rejection, some elaborate methods, such as gene therapy,
are under investigation [3,110].
ESCs are characterized by genetic instability and
imprinting genes dysregulation [111]. Indeed, their
transplantation in rodents is associated to higher risk of
malignant transformations, such as teratomas or terato-
carcinomas [112-114], although the tumorigenic poten-
tial of ESC seems to be greatly reduced when the cells
are predifferentiated in vitro before implantation [115].
The graft of ESCs must be preceded by an accurate
functional characterization to distinguish partially trans-
formed and potentially oncogenic clones and normal
cells [116].
Medical tourism
In developing countries some doctors are treating
patients with ASC without waiting for clinical trials to
validate the safety of using them for health problems
[117].
In treatments, involving the use of ASC, the cells are
injected into the blood, lumbar region, or damaged tis-
sue. The only treatments using ASC that are proven by
clinical trials, are concerned with blood disorders, bone
marrow transplantation and rare immune deficiencies.
Several cases of patients, who developed serious side
effects following SC transplantation, such as brain
tumors, after injections of fetal neural SC, or meningitis
have been reported [118].
A Google search, using the key words ‘’stem cell ther-
apy’’ or ‘’treatment’’, has outlined the range of treat-
ments being offered directly to consumers. Websites
generally describe therapies as safe, effective, and ready
for routine use in a wide variety of conditions. In con-
trast, the published clinical evidence has been unable to
support the use of these therapies for the routine disease
treatment. Patients must receive sufficient and appropri-
ate information and fully understand the risks. Clinics
must also contribute to public expectations without
exceeding what the field can reasonably achieve. How-
ever, this interpretation is subject to the following lim-
itations: information, available from websites, could not
be indicative of the information actually shared with
patients during their clinical encounters; the aggregate
data, collected from a heterogeneous group of clinics,
could not be used to evaluate the claims of any particu-
lar clinic; and finally, the accuracy of websites’ claims
has not been tested directly by analyzing actual outcome
data. Instead, there is a lack of high quality evidence
supporting SC clinics’ claims. Even supposing that
clinics have indeed observed successful recovery from
chronic disease post-treatment, a lack of good evidence
precludes a valid or precise inference that the observed
improvement is attributable to the interventions. If, in
fact, the interventions had not been effective, then the
patients would have been subjected to inappropriate
risks and exaggerated financial burden [119,120].
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Autoimmune disease
Rheumatoid arthritis and juvenile idiopathic arthritis
Rheumatoid arthritis (RA) is the progressive and irrever-
sible erosion of the cartilage tissue of joint with the con-
sequent loss of mobility, pain and reduction in the
quality of life. Probably, RA and juvenile idiopathic
arthritis (JIA) are caused by failure of tolerance and
immune response against joint tissue antigens and
aptens with abundant release of inflammatory cytokines
and autoantibody [121,122]. Standard therapy encloses
nonsteroidal medications with slow addition of tradi-
tional disease-modifying anti-rheumatic drugs
(DMARDs) or intra-articular corticosteroid injections,
but the remission rate is only about 15% [123].
Several clinical trials have been conducted to treat RA
and JIA with autologous HSCs transplantation
(AHSCT).
A significant response has been obtained in most sub-
jects in a study involving 76 patients with severe RA
which were resistant to conventional therapies and sub-
mitted to AHSCT. Although the disease has not been
cured, recurrent or persistent disease activity has been
controlled, in some cases, with common antirheumatic
drugs [124]. A trial, involving 33 patients with severe,
refractory RA, randomly submitted to either AHSCT or
selected CD34+ infusion, has not shown any advantage
with antigen selection, but it has confirmed immunomo-
dulatory action of HSC in joint microenvironment [125].
A successfully HSCT protocol has been proposed to
treat severe JIA, harvest BM, select positive SCs, deplete
T cells, re-infuse the cells and administer antiviral drugs
and immunoglobuline until the immune system returns
to full competence to avoid frequent infection [126].
Systemic lupus erythematosus
Systemic lupus erythematosus (SLE) is a multi-system,
inflammatory, autoimmune disease, caused by BM
microenvironment dysfunction and consequently a
marked reduction of number and proliferative capability
of HSCs with a hyperproduction of immunocomplex.
Cells CD34+ undergo an elevated apoptosis rate. SLE
includes nephritis, serositis, pneumonitis, cerebritis, vas-
culitis, anti-phospholipid antibody syndrome with
venous and vascular thrombi, arthalgias, myalgias, cuta-
neous symptoms [127]. Usually SLE is aspecifically trea-
ted with non-steroidal anti-inflammatory drugs,
antimalarials, corticosteroids and cytotoxic agents. How-
ever, every drug involves severe side effects and frequent
relapses [128].
AHSCT has reduced the number of apoptotic CD34+
cells pre-treatment [22]. In the last decade, contrasting
results have been reported in literature. AHSCT has
been performed on 15 patients with severe SLE with a
general positive outcome. Only two subjects have had a
recurrence of symptoms [129]. However, it has been
reported a lower disease free rate and high mortality
[130]. Further trials are required, but it seems probable
that HSCT can be used not with a curative intent, but
to mitigate the disease impact towards a more drug sen-
sitive type. However, it should be reserved only for
those patients with persistence of organ-threatening
SLE, despite the standard aggressive therapy [131].
Multiple sclerosis
Multiple Sclerosis (MS) is a life-threatening, physically
and psychologically debilitating autoimmune disease
(AD), mediated by T cells triggered against structural
components of myelin and consequent degenerative loss
of axon in the central nervous system (CNS). In fact,
the nerve atrophy progressively reduces the electrical
signalling neurons muscles and related mobility. The
inflammatory reaction is an important component of
MS physiopathology and the conventional treatments
aims at reducing it in order to cure or postpone course
disease [132,133]. Two types of MS can be identified:
primary progressive MS (PPMS), generally resistant to
treatment and without amelioration, and secondary pro-
gressive MS (SPMS) with episodic relapse and improve-
ment [134].
As gold standard therapy efficiently delays MS pro-
gression for many years, AHSCT have been performed
o np a t i e n t sw h od on o tr e s p o n dt oc o n v e n t i o n a lt h e r a -
pies, and consequently the results have not been
encouraging and, in several cases, they have taken a
turn for the worse [135]. Furthermore, graft exposes
patients to infection risks, localized toxicity or autoim-
mune diseases [136,137]. However, it has been reported
a reduction of CNS inflammation with a stabilization of
the disease in patients aged less than 40 years [136].
A plastic conversion of HSC-derived cells, to replace
damage neurons, has been hypothesized [138].
Systemic sclerosis
Systemic sclerosis (SSc) is a multisystem, rare disorder
characterized by cutaneous and visceral (pulmonary,
cardiac, gastrointestinal and renal) fibrosis as a conse-
quence of T cell activation, autoantibody production,
cytokine secretion and excessive collagen deposition.
Patients with the diffuse variant, who have extensive
skin and early visceral involvement, have a poor out-
come with a 5-year mortality which is estimated at
40-50% in 5 years [139]. The therapy for the SSc is far
from being perfect. At present, the best results are
obtained with the combination of cyclophosphamide
(CY) and angiotensin [140].
It has been demonstrated that AHSCT improves the
skin flexibility and stabilizes the pulmonary involvement
[141-146].
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ing results. The first describes a long time remission
rate of 80% (partial or complete) on 57 patients, and the
majority of the subjects have presented a general
improvement of pre-AHSCT clinical condition. The sec-
ond study, instead, shows a higher reactivation rate
(50%). Interestingly, AHSCT can extend the short life
expectancy of patients with severe SS [147].
Ultimately, priming regimens, i.e. a disease progression
and transplant procedure, that is transplanted-related
complication, have been associated to high mortality
rates (27%) [143].
Crohn’s disease
It is an incompletely known autoimmune disease char-
acterized by the gastrointestinal loss of immune toler-
ance caused by overactive T-helper 1 response. The
environmental agents and genetic factors are also
involved. Sometimes the disease can be controlled by
immunosuppressive drugs, antibodies and surgical inter-
vention [148]. AHSCT has proved safe and can be able
to induce and maintain remission in previously refrac-
tory patients affected by Crohn’s disease [149,150].
By combining AHSCT with CY, a clinical remission
with a disappearance of diarrhea, and a reduction in the
abdominal pain and activity have been obtained [151].
Autoimmune cytopenias
In immune thrombocytopenia purpura (ITP), the platelets
are removed from blood by autoantibodies and the effects
are thrombocytopenia and bleeding. Usually, ITP cases are
responsive to high doses of immunosuppressors; neverthe-
less this treatment exposes them to myelosuppression
risks. HSCT can accelerate the reestablishment of the
hematological parameters, while the number of autoim-
mune cells in the body decreases [152]. An American
study has showed the efficacy of a combined therapy of
CY and AHSCT in chronic refractory ITP treatment. The
majority of patients show a long term response, suggesting
that SCs can accelerate the hematological re-balance com-
pared with classic immunotherapy [153]. A study by Eur-
opean Bone Marrow Transplantation (EBMT) reports the
treatment of 12 cases of ITP with AHSCT. However, the
responses to treatment have varied from a transient
response to a continuous remission or even death related
to transplantation [154]. Immune haemolytic anemia
(IHA) is a hematologic disease characterized by an early
destruction of erythrocytes due to an autoreaction of anti-
bodies or complement against the membrane protein
[155-157]. The few reports available do not permit to gain
definitive conclusions. It has been suggested that the asso-
ciation between the AHSCT and immunosuppressive ther-
apy can be an effective treatment for IHA [158]. However
it has also been showed a high failure rate or even death
after HSCT [159].
Diabetes Mellitus
Type I diabetes mellitus (DM) results in a cell-mediated
autoimmune attack against insulin-secreting pancreatic
b-cells. Insulin regulates glucose homeostasis and, in
particular, it reduces glycemia when glucose exceeds in
blood. Glucose accumulation, which is typical of dia-
betes, damages blood vessels causing the decrease of cell
perfusion. Other complications are diabetic neuropathy,
consisting of a gradual loss of hand, foot and limb
mobility caused by nerve degeneration, retinopathy,
characterized by loss of vision and blindness for light-
sensitive retina atrophy, nephropathy with a loss of
removing wastes and excess water and urinary tract
infection with a glucose rich urine which favours bac-
teria proliferation. The common therapy consists in the
chronic introduction of exogenous insulin to restore
glucose homeostasis, although resistance to this therapy
has been observed [160-163]. SC transplantation can
rehabilitate pancreatic islets and reintroduce physiologi-
cal secretion of human insulin.
AHSCT improves b-cells function and frequently
decreases the exogenous insulin need [20] or induces a
persistent insulin independence and normal glycemic
control when grafted in type 1 DM subjects [164].
Combining CY with AHSCT , an insulin-free period is
achieved [22]. In particular it has been proposed a
synergic action of CY and AHSCT to explain exogenous
insulin independence. This has been shown in the first
successful Polish attempt to achieve remission in the
early phase of type 1 diabetes mellitus following immu-
nosuppressive treatment and the subsequent AHSCT.
The method involves the destruction of the patient’s
immune system and also the autoimmune process
which is the main pathomechanism in type 1 diabetes
mellitus. As soon as the autoaggressive mechanism is
stopped, pancreatic cells might be able to resume secre-
tion of sufficient amounts of insulin to maintain normal
glucose level [165]. Allotropic human adipose tissue
derived, insulin-making mesenchymal SCs (h-AD-MSC)
have been transfused with unfractionated cultured BM
in insulinopenic DM patients without side effects.
Furthermore, an appreciable insulin requirement
decrease has been observed [166].
Neurological disorders
Amyotrophic lateral sclerosis
Amyotrophic lateral sclerosis (ASL) is caused by the
progressive death of central and peripheral motor neu-
rons. The subjects affected by ALS show a severe motor
dysfunction. In several cases the mutation of the super-
oxide dismutase gene is inherited, but often its origin is
unknown. ALS is not a typical AD because autoimmune
and inflammatory abnormalities are not an etiological
cause of the disease, even if they influence its
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intended to protect neurons from degeneration and to
stimulate cell regeneration. At the moment, no drug
treatment restores the neural cells. SCs therapy is a pro-
mising strategy that can combine neuroprotection with
the recovery of the neuromotor function [167].
Intrathecal injection of selected HSC or MSC have
resulted safe and have afforded a partial neurological
function improvement in patients with severe ALS
[168,169].
Ex vivo expanded AHSC spinal injection, in patients
with severe impairment of the lower limb by ALS, has
also showed cell number-related improvement of gen-
eral condition, i.e. a deceleration of the leg muscular
strength loss and a respiratory function decline. Side
effects, such as intercostal pain or dysesthesia have only
been slight and reversible, but they sometimes persist
after 2 years from treatment [170].
AHSCT into the frontal motor cortex in ALS patients
has delayed the disease progression and has improved
the quality of life [171].
Many cases of ALS patients, treated with autologous
SCs (mesenchymal and hematopoietic) and injection
(intraspinal thoracic or in motor cortex), have been
reported. A deceleration of forced vital capacity linearly
declines and an improvement in functionality has been
described, probably due to an immunomodulatory effect
[172].
Parkinson’s disease
Parkinson’s disease (PD) is a debilitating neurodegenera-
tive disorder caused by selective and gradual loss of
nigrostriatal dopamine-containing neurons [112]. Dopa-
minergic neurons are localized in the substantia nigra
pars compacta and project on to striatum. A degenera-
tion of these cells leads to neural circuit anomaly in the
basal ganglia that regulate movement. The main symp-
toms are rigidity, bradykinesia, tremor and postural
instability [173]. Pharmacological treatments, such as
levodopa/carbidopa, dopamine agonists, MAO-B inhibi-
tors, and COMT inhibitors, are effective to control PD
symptoms but they are unable to stop neural degenera-
tion and replace dead cells [174]. In this context SCs
seem to be promising since they can stimulate the
recovery of neuromotor function. PD patients, who had
received unilaterally striatum human embryonic mesen-
cephalic tissue implants twice, have showed movement
improvements (different degrees) and DOPA (dopamine
precursor) increased levels [175,176]. Symptoms and F-
fluorodopa (marked analogous) uptake have significantly
improved in PD patients younger than 60 [177].
Bilateral fetal nigral graft, in PD patients, has also
resulted safe and quite effective. Fluorodopa uptake has
increased, but in about half of the patients dyskinesia
has remained unchanged [178,179].
Spinal cord lesions
Spinal trauma can break ascending and descending axo-
nal pathways with consequent loss of neurons and glia,
inflammation and demyelination. Depending on the
injury site, functional effects, induced by cellular
damage, are inability of movement, sensorial loss and/or
lack of autonomic control. No therapies for spinal
trauma exist. However, interesting results have been
obtained with SCs transplantation [112].
Based on the discovery that olfactory mucosa is an
important and readily disposable source of stem like
progenitor cells for neural repair, the effects of its
intraspinal transplant on spinal cord injured patients
have been shown. All the patients have improved their
motor functions either upper extremities in tetraplegics
or lower extremities in paraplegics. The side effects
include a transient pain, relieved with medication, and
sensory decrease [180]. Generally, the olfactory mucosa
transplant is safe, without tumor or persistent neuro-
pathic pain [181]. Neurological improvements have also
been observed in spinal cord injury patients treated with
intra-spinal autologous BMC graft. The best results have
been obtained in patients transplanted 8 weeks before
the trauma [182].
Huntington’s disease
Huntington’s disease (HD) is a fatal, untreated autoso-
mal dominant characterized by CAG trinucleotide
repeats located in the Huntington’s gene. This neurode-
generative disorder is characterized by chorea, i.e. exces-
sive spontaneous movements and progressive dementia.
The death of the neurons of the corpus striatum causes
the main symptoms [112]. At the moment, no therapies
for HD exist although SCs can contrast the neurodegen-
eration characteristic of the disease. In a HD patient,
who died 18 months after human fetal striatal tissue
transplantation for a cardiovascular disease, postmortem
histological analysis has showed the survival of the
donor’s cells. No histological evidence of rejection has
been observed. The donor’s fetal neural cells do not
have mutated huntingtin aggregate and currently are
s u p p o s e dt ob ea b l et or e p l a c et h ed a m a g e dh o s t
neurons and reconstitute the damaged neuronal connec-
tions [183].
Several studies have emphasized safety [184,185], the
donor’s cells survival [183] and the functional efficacy
[186,187] of intracerebral fetal striatal transplantation
practice.
However, three cases of post-graft subdural hemato-
mas, in late-stage HD patients, have been reported. The
same authors have observed that striatal graft, in heavily
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risk [188].
Stroke
The obstruction of a cerebral artery leads to focal ische-
mia, loss of neurons and glial cells with the consequent
motor, sensory or cognitive impairments. Recent
advances in thrombolysis and in neuroprotective strate-
gies allow managing acute stroke. When drugs are admi-
nistered few minutes after the injury and the damage is
not severe, it is possible to restore the normal functions
[112]. Interesting results are also obtained with the SC
therapy.
A subarachnoidal injection of immature nervous cells
and hematopoietic tissue suspension, in patients with
brain stroke, have significantly improved the functional
activity without serious side effects [189].
Progressively, neurological deficits have decreased in
cerebral infracted patients, when treated with intrave-
nous MSCs infusion. No adverse cell-related, serological
or imaging defined effects have been observed [190].
Interesting results have been obtained with the granu-
locyte colony-stimulating factor (G-CSF) in the acute
cerebral infarction management. G-CSF has mobilized
HSCs, improving the metabolic activity and the neurolo-
gic outcomes [191].
Duchenne muscular dystrophy
Duchenne muscular dystrophy (DMD) is a severe reces-
sive X-linked muscular dystrophy characterized by pro-
gressive muscle degeneration, loss in ambulation,
paralysis, and finally death. DMD is caused by mutations
on the DMD gene, located on the X chromosome. DMD
symptoms are principally musculoskeletal, i.e. muscle
fiber and skeletal deformities, difficulties in motor skills
and fatigue, but they can regard one’s behavior and
learning. To date, no cures for DMD are known, while
treatments, such as corticosteroids, physical therapy and
orthopedics appliance can control the symptoms to
maximize the quality of life [192]. Recent developments
in SC research suggest the possibility to replace the
damaged muscle tissue.
Allogenic, combined with CY, or autologous myoblast
transplantation in DMD patients is a safe procedure. No
local or systemic side effects have been reported
[193,194]. In particular, using fluorescence in situ hybri-
dization (FISH), myoblast allograft has showed the
donor’sn u c l e if u s e dw i t ht h eh o s t ’sn u c l e ia n dd y s t r o -
phin wild type increased [195]. Therefore distrophin
mRNA has been detected using polymerase chain reac-
tion (PCR), six months after graft [196]. However, many
authors have reported that myoblast injection in DMD
patients do not improve their strength [194], even if
the injection site, CY dose or blast number have
changed [196,197]. An injection-triggered cellular
immune response in the host has been discovered.
The antibodies producted are capable to fix the comple-
ment and destroy new myotubes. Probably distrophin is
an antigen recognized by the host immune system [198].
Heart failure
Heart failure is commonly caused by myocardial infarc-
tion (MI). MI is the ischemic necrosis of the cardiac tis-
sue and it is frequently triggered by severe coronary
stenosis. The myocyte fall produces abnormal left-
ventricular remodelling the chamber dilatation and con-
tractile dysfunction [199]. The rapid reperfusion of the
infarct related coronary artery is the primary manage-
ment to reduce the ischemic area and avoid the myocar-
dic tissue damage. The percutaneous transluminal
coronary angioplasty, with a stent implantation, is the
gold standard method to reestablish the coronary flow.
Unfortunately, angioplasty is effective only if executed
rapidly and expertly, otherwise the myocardial necrosis,
which starts several minutes after the coronary occlu-
sion, commits the cardiac function [200]. Many studies
suggest that SCs can improve heart function by repair-
ing the cardiac tissue.
The major multicenter trial on MI treatment with
autologous skeletal myoblast transplantation, has
reported the failure of cell therapy in heart dysfunction.
No improvements in the echocardiographic heart func-
tion have been underlined, neither general health has
taken a turn for the worse [201]. However, other studies
have described the efficacy of myoblast transplant in the
ejection fraction (EF) improvement in MI patients
[202,203].
Instead, AHSCT improves cardiovascular conditions in
MI patients, such as ejection fraction, and it avoids
harmful left ventricular remodelling [204].
In particular, intracoronary infusion of HSCs is asso-
ciated with a significant reduction of the occurrence of
major adverse cardiovascular events after MI, such as
MI recurrence restenosis or arrhythmia [205,206].
Ocular surface diseases
Ocular surface diseases are characterized by persistent
epithelial defects, corneal perfusion problems, chronic
inflammation, scarring and conjunctivalisation resulting
in visual loss. These pathologies are associated with a
limbal SC deficiency (LSCD). LSCD derives from heredi-
tary disorders, such as aniridia, keratitis, or acquired dis-
orders, such as Stevenson-Johnson syndrome (SJS),
chemical injuries, ocular cicatricial pemphigoid, contact
lens-induced keratopathy, multiple surgery or limbal
region cryotherapy , neurotrophic keratopathy and per-
ipheral ulcerative keratitis conditions [207]. Obviously,
SC transplantation is the only effective therapy that can
restore the ocular environment.
A study conducted on a homogeneous group of
patients with limbal cell deficiency has been conducted
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eye. Fibrin cultures were grafted onto damaged corneas
observing that: 1) fibrin-cultured limbal SCs were suc-
cessful in 14 of 18 patients; 2) re-epithelialization
occurred within the first week; 3) inflammation and vas-
cularization regressed within the first 3-4 weeks; 4) by
the first month, the corneal surface was covered by a
transparent, normal-looking epithelium; 4) at 12-27
months follow-up, corneal surfaces were clinically and
cytologically stable. Their visual acuity improved from
light perception or counting fingers to 0.8-1.0 [208].
Limbal allograft also corrects acquired and hereditary
LSCD recovering the visual activity [209-211]. It has
been reported a retrospective study on endothelial rejec-
tion in central penetrating graft after a simultaneous
keratolimbal allograft transplantation (KLAT) and pene-
trating keratoplasty (PKP) using the same donor’sc o r -
nea. A third cohort of treated patients have rejected
transplant. After an immunosuppressive therapy, the
majority of rejects have restored the corneal clarity
while in the others neovascularization has developed
into the grafted limbs [212].
Cartilage repair
Osteoarthritis (OA) is a degenerative joint disease, char-
acterized by accumulated mechanical stresses to joints
and leading to the destruction of articular cartilage.
A synovial fluid decrease has also been observed [213].
OA and peripheral joint injuries are commonly treated
with interventional pain practice, exercise therapy, ultra-
sound or electromagnetic device after surgery, although
t h e s et h e r a p i e sh a v en o tp r o v e nt ob ead e f i n i t i v es o l u -
tion [214-217]. SCs seem to be a promising solution to
overcome OA cartilage destruction. The first autologous
mesenchymal SC culture and percutaneous injection
into a knee with symptomatic and radiographic degen-
erative joint disease has been reported and it has
resulted in significant cartilage growth, decreased pain
and increased joint mobility. This has significant future
implications for minimally invasive treatment of osteoar-
thritis and meniscal injury treated with percutaneous
injection of autologous MSCs expanded ex-vivo has
been reported [218].
Liver disease
Cirrhosis is a progressive liver function loss caused by
fibrous scar tissue replacement of normal parenchyma.
Cirrhosis is commonly caused by alcoholism, hepatitis B
and C and fatty liver disease, but there are many other
possible causes. Cirrhosis is generally irreversible and
treatments are generally focused on preventing its pro-
gression and complications. Only liver transplant can
revert the pathological condition if there is a terminally
ill patient [219]. SC therapy can contrast liver degenera-
tion and block cirrhosis progression.
AHSC infusion in cirrhotic patients has improved liver
parameters, such as transaminase, bilirubin decrease and
albumin increase [220,221]. After infusion, proliferation
indexes, such as alpha fetoprotein and proliferating cell
nuclear antigen (PCNA), have significantly increased,
suggesting that HSCs can enhance and accelerate
hepatic regeneration [222]. No significant side effects
have been registered [223].
Cancer
Renal cell cancer
Renal cell cancer (RCC) is the most frequent kidney
cancer. RCC originates in the lining of the proximal
convoluted renal tubule. RCC appears as a yellowish,
multilobulated tumor in the renal cortex, which fre-
quently contains zones of necrosis, hemorrhage and
scarring. The signs may include blood in the urine, loin
pain, abdominal mass, anaemia, varicocele, vision
abnormalities, pallor, hirsutism, constipation, hyperten-
sion, hypercalcemia, night sweats and severe weight loss.
The initial treatment is commonly a radical or partial
nephrectomy. Other treatment strategies, including hor-
mone therapy, chemotherapy, and immunotherapy, have
little impact on global survival [224,225]. HSCT can be
an important tool for the management of RCC, in parti-
cular under the metastatic form.
HSCT, combined with the immunosuppressive or
donor’s lymphocyte infusion (DLI), can improve the
general condition in metastatic RCC patients. Three fac-
tors, i.e. performance status, C-reactive protein (CRP)
level and lactate dehydrogenase (LDH) level, have been
found and they are significantly associated with a major
success of allograft [226]. HSCT have trigged graft ver-
sus tumor (GVT) response, reducing the metastasis and
reaching out the survival time [227-229].
Breast cancer
Breast cancer (BR) refers to cancers originating from the
breast tissue, commonly from the inner lining of milk
ducts or the lobules that supply the ducts with milk.
Occasionally, BR presents as a metastatic disease with
spreads in bones, liver, brain and lungs. The first evi-
dence or subjective sign of BR is typically a lump that
feels different from the rest of the breast tissue. Other
symptoms can be: changes in breast size or shape, skin
dimpling, nipple inversion, or spontaneous single-nipple
discharge. Pain ("mastodynia”) is an unreliable tool to
determine the presence or absence of BR, but it may be
indicative of other breast health issues. When the cancer
cells invade the dermal lymphatics (small lymph vessels)
in the breast skin, BR appears as a cutaneous inflamma-
tion. In this phase symptoms include pain, swelling,
warmth and redness throughout the breast, as well as an
orange peel texture to the skin, referred to as “peau
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therapy and chemotherapy), and radiation, which are
effective against non metastatic forms [230]. SCT can
increase survival in patients with spreading BR.
A high dose chemotherapy (HDC) with SC support
has improved the disease free survival in metastatic BR.
However, HDC has induced serious cytotoxicities [231].
In reduced intensity conditioning regimens (RICT), allo-
geneic HSCT has proven to be effective in persistent
and progressive metastatic BR, decreasing relapse. Allo-
geneic SC transplantation with myeloablative condition-
ing regimens may provide cytoreduction and eradication
of disease with a cancer free-graft and an immune-
mediated graft-versus-tumor (GVT) effect mediated by
the donor’s immune cells [232,233].
Colorectal cancer
Colorectal cancer (CRC) includes cancerous growths in
the colon, rectum and appendix. Many CRCs are
thought to arise from adenomatous polyps in the colon.
These mushroom like growths are usually benign, but
some may develop into cancer over time. Symptoms
and signs are divided into: local ones, consisting in
change in bowel habits and in frequency, such as consti-
pation and/or diarrhea, feeling of incomplete defecation
(tenesmus) and reduction in tool diameter, bloody stools
or rectal bleeding, stools with mucus, black and tar-like
stool (melena), bowel pain, bloating and vomiting,
hematuria or pneumaturia, or smelly vaginal discharge;
constitutional ones i.e. weight loss, anemia, dizziness,
fatigue and palpitations; metastatic ones, i.e. liver metas-
tases, causing Jaundice, pain in the abdomen, liver enlar-
gement and blood clots in veins and arteries. Surgery is
the usual therapy and, in many cases, is followed by
chemotherapy [234-236]. The gastrointestinal tract is a
target of GVHD in transplants and, therefore, CRC,
might be treated by allogeneic SCT. Four cases of meta-
static CRC, undergoing reduced-intensity SC transplan-
tation (RIST), have been reported. No significant graft
toxicities have been registered. CRC markers have
decreased in three patients after allograft. Three patients
died of disease progression, but postmortem examina-
tion has showed a macroscopic metastatic lesion disap-
pearance [237]. The patients with progressing metastatic
CRC, treated with RIST, have showed relevant results in
terms of tumor response. Even metastatic CRC need
intense GVT to eradicate spreading tumor cells. Allo-
geneic SCT is likely to have trigged the generation of
anti-neoplastic T cells [238-240].
Ovarian cancer
Ovarian cancer (OC) is a cancerous growth arising from
different parts of the ovary. Commonly, OC arises from
the outer lining of the ovary, but also from the Fallopian
tube or egg cells. OC is characterized by non-specific
symptoms and, in early stages, it is associated with
abdominal distension. Many women with OC report one
or more non-specific symptoms, such as an abdominal
pain or discomfort, an abdominal mass, bloating, back
pain, urinary urgency, constipation, tiredness, and some
specific symptoms, such as pelvic pain, abnormal vaginal
bleeding or involuntary weight loss. There can be a
build-up of fluid (ascites) in the abdominal cavity.
A surgical treatment may be sufficient for malignant
tumors that are well-differentiated and confined to the
ovary. An addition of chemotherapy may be required for
the most aggressive tumors that are confined to the
ovary. For patients with an advanced disease, a surgical
reduction is combined with a standard chemotherapy
regimen. Some studies describe the feasibility of the
combination of chemotherapy with SCT [241].
Allogeneic HSCT, associated with chemotherapy in
advanced OC, treatment has induced variable effects.
When SCs infusion trigger GVT, it is possible to control
the disease progression [242,243]. However, GVT does
not occur frequently. No serious side effects have been
registered [244,245].
Lung cancer (LC)
LC is characterized by an uncontrolled cell growth in
the lung tissue. Frequently LC rises from the epithelial
cells. The small cell lung carcinoma (SCLC) is the most
frequent lung carcinoma. The symptoms can result from
the local growth of the tumor (coughing up blood,
shortness of breath and chest pain), a spread to the
nearby areas (hoarseness of voice, shortness of breath,
difficulty in swallowing, swelling of the face and hands),
a distant spread (the spread to the brain can cause head-
ache, blurring of vision, nausea, vomiting, and weakness
of any limb, a spread to the vertebral column which can
cause back pain, a spread to the spinal cord which can
cause paralysis, a spread to the bone that may lead to
bone pain and a spread to the liver possibly causing
pain in the right upper part of the abdomen), paraneo-
plastic syndromes, or a combination of them. Possible
treatments are surgery, chemotherapy, and radiotherapy
[246]. An addition of SCT can improve the survival rate
and avoid relapses. AHSCT has been frequently com-
bined with chemotherapy in SCLC treatment. The rea-
son is that HSCs drastically reduce the chemotherapy
side effects, in particular myeloablation [247-249]. Prob-
ably, HSCs may also induce therapeutic effects contrast-
ing the tumor directly [250]. In SCLC, HSCs trigger
GVT and increase the survival rate.
Leukemia
Leukemia is the uncontrolled proliferation of the mye-
loid or lymphoid blood line and the consequential blast
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acute myeloid leukemia (AML), chronic myeloid leuke-
mia (CML), acute lymphoblastic leukemia (ALL) and
chronic lymphocytic leukemia (CLL). Leukemia is
caused by a mutation in the gene involved in the cell
proliferation. The first signs and symptoms of leukemia
are nonspecific and they include fatigue, malaise, and
abnormal bleeding, excessive bruising, weakness,
reduced exercise tolerance, weight loss, bone or joint
pain, infection and fever, abdominal pain or “fullness”,
enlarged spleen, lymph nodes and liver,. Moreover a
high white blood cell count is detectable. Chemotherapy
is the initial treatment of choice, but only with the sub-
stitution of the malignant blast with the normal SCs,
leukemia can be eradicated [251-256].
Many studies indicate allogenic RIST as an important
p r o c e d u r et oa c h i e v eac o m p l ete remission in patients
with leukemia, especially if a human leukocyte antigen
compatible donor is employed [257-265]. GVHD is the
major limiting factor for successful transplantation, but
its frequency is sensibly reduced if compared to the first
treatment [266,267]. The mortality rate has also
decreased significantly [268].
Guidelines For Scs Application
SCs transplantation in human patients must ensure
safety and therapeutic efficacy. Preclinical studies aim at
providing persuasive evidence, in an appropriate in vitro
and/or animal model, which supports the likelihood of a
relevant positive clinical outcome. Preclinical testing in
animal models, whenever feasible, is especially important
for SC based approaches because SCs can act through
multiple mechanisms. Physiological integration and
long-lived tissue reconstitution are hallmarks of SC
based therapeutics for many disease applications. Ani-
mal models will be important to assess possible adverse
effects of implanted cellular products. The need for ani-
mal model is especially strong in the case of extensive
ex vivo manipulation of cells and/or when the cells have
been derived from pluripotent SCs.
It should be acknowledged, however, that preclinical
assays, including studies in animal models, may provide
limited insight into how transplanted human cells will
behave in human recipients due to the context depen-
dent nature of the cell behavior and recipient’si m m u n e
response. These uncertainties must be borne in mind
during the independent peer review of the preclinical
data. Only when the compelling preclinical data are
available, careful and incremental testing in patients is
justified. Preclinical studies must be subject to rigorous
and independent peer review and regulatory oversight
prior to the initiation of the clinical trials, in order to
ensure that the performance of the clinical studies is
scientifically and medically warranted. Because new and
unforeseen safety concerns may arise with the clinical
translation, frequent interaction, between preclinical and
clinical investigators, is strongly encouraged. The clini-
cal trials of SC based interventions must follow interna-
tionally accepted principles governing the ethical
conduct of the clinical research and the protection of
the human subjects. Key requirements include regula-
tory oversight, peer review by an expert panel indepen-
dent of the investigators and sponsors, fair subject
selection, informed consent and patient monitoring.
However, there is a number of important SC related
issues that merit a special attention [269]. The guide-
lines concerning the preclinical studies (animal model),
clinical studies have been summarized in the “Guide-
lines for the Clinical Translation of Stem Cells” pub-
lished in 2008.
Conclusions
This review shows the most interesting clinical trials in
SC biology and regenerative medicine [270-272]. Pro-
mising results have been described in disorders, such as
diabetes [273] and neurodegenerative diseases [274,275],
where SCs graft can reestablish one or more deficit cel-
lular lineages and, generally, a healthy state. Notably,
many clinical studies have underlined the immunomo-
dulatory effect of SCs in autoimmune diseases, such as
multiple sclerosis [275], organ transplants [276] and in
uncontrolled immune-inflammatory reactions [277-279].
Probably, SCs induce immune suppression and inhibit
proliferation of alloreactive T cells [280]. Moreover, SCs
are at the core of the huge framework of cellular ther-
apy and are going to be used in the gene therapy
[281,282] or as scaffolds in SCNT [109]. An interesting
cell type is the induced pluripotent stem cell (iPSC)
[283]. iPSCs are artificial cells derived from non pluripo-
tent cells, typically adult somatic cells through the
induction of a “forced” expression of specific genes.
iPSCs have been regarded as the most promising way
to create SCs. However the use of iPSCs has raised con-
cerns. The iPSCs are easily created by modulating the
human genome to ectopically express transcriptional
factors. Since their overexpression has been associated
with tumorigenesis [284,285], there is a risk that the dif-
ferentiated cells might also be tumorigenic when trans-
planted into patients. The insertion of transgenes into
functional genes of the human genome can be detri-
mental [286]. Furthermore, although the transcription
factors are mostly silenced following reprogramming, it
has been reported that residual transgene expression
may be responsible for some of the differences between
ESCs and iPSCs such as the altered differentiation
potential of iPSCs into functional cell types [287]. There
are a few ways of creating iPSCs, i.e. genomic modifica-
tion, protein introduction, and treatment with chemical
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keeping in mind ethical, legal, and social issues [290].
T h e s ec e l l sm a yb eu s e dt oc o n s t r u c td i s e a s em o d e l s
and to screen effective and safe drugs, as well as to treat
patients through the cell transplantation therapy [281].
However, the validity of these predictions will depend
on the benefits obtained on the ongoing phase II and III
human clinical trials. In the meantime, new candidate
small molecules and bioactives will be identified using
SC assays in the high-throughput screening that will
impact on SC mobilization broaden the horizons of
regenerative medicine. It has been proposed that cente-
narians and supercentenarians (aged 110 years or more)
may present an unprecedented opportunity to explore
the possibilities of SCs that have proven their value over
time. These SCs should be studied to determine their
developmental potential, mutational load, telomere
lengths, and markers of “stemness” [291]. In conclusion,
beyond the great enthusiasm for new treatment perspec-
tives, an heavy investigational work is still in progress to
develop specific SCs related pharmacology. In fact new
drugs are urgently needed to assist SCs in vitro/in vivo
differentiation and full tissue/organ integration and
recovery. As far as CNS related diseases (cerebrovascular
accidents and spinal traumatic lesions) are concerned,
the role of autologous cytokines induced by SCs infu-
sion has to be deeply investigated and may represent, in
the future, a new treatment perspective.
Abbreviations
(ADSC): Adipose Tissue-Derived Stromal Cell; (ASC): Adult Stem Cell; (ALL):
Acute Lymphoblastic Leukemia; (AML): Acute Myeloid Leukemia; (ASL):
Amyotrophic Lateral Sclerosis; (AD): Autoimmune Diseases; (AHSCT):
Autologous HSCT; (BM): Bone Marrow; (BR): Breast Cancer; (BOOP):
Bronchiolitis Obliterans Organizing Pneumonia; (CNS): Central Nervous
System; (CML): Chronic Myeloid Leukemia; (CLL): Chronic Lymphocytic
Leukemia; (CRC): Colorectal Cancer; (CRP): C-Reactive Protein; (CY):
Cyclophosphamide; (DM): Diabetes Mellitus; (DMARD): Disease-Modifying
Anti-Rheumatic Drug; (DLI): Donor Lymphocyte Infusion; (DMD): Duchenne
Muscular Dystrophy; (EF): Ejection Fraction; (EC): Embryonic cell; (EGC):
Embryonic Germ Cell; (ESC): Embryonic Stem Cell; (EBMT): European Bone
Marrow Transplantation; (FSC): Fetal Stem Cell; (GVHD): Graft Versus Host
Disease; (GVT): Graft Versus Tumor; (HSC): Haematopoietic Stem Cell; (HDC):
High-Dose Chemotherapy; (HSCT): HSC Transplantation; (h-AD-MSC): Human
Adipose-Tissue-Derived insulin-making Mesenchymal SCs; (HD): Huntington’s
Disease; (IHA): Immune Haemolytic Anemia; (ITP): Immune
Thrombocytopenia Purpura; (iPSC): Induced Pluripotent Stem Cell; (ICM):
Inner Cell Mass; (JIA): Juvenile Idiopathic Arthritis; (KLAT): Keratolimbal
Allograft Transplantation; (LDH): Lactate Dehydrogenase; (LONIPC): Late-
Onset Non-Infectious Pulmonary Complications; (LSCD): Limbal SC
Deficiency; (LC): Lung Cancer; (MHC): Major Histocompatability Complex;
(MSC): Mesenchimal Stem Cell; (MS): Multiple Sclerosis; (MI): Myocardial
Infarction; (OB): Obliterative Bronchiolitis; (OA): Osteoarthritis; (OC): Ovarian
Cancer; (PD): Parkinson’s Disease; (PCR): Polymerase Chain Reaction; (PPMS):
Primary Progressive MS; (PCNA): Proliferating Cell Nuclear Antigen; (RIST):
Reduced-Intensity Stem-Cell Transplantation; (RICT): Reduced-Intensity
Conditioning Regimens; (REB): Research Ethics Board; (RA): Rheumatoid
Arthritis; (RCC): Renal Cell Cancer; (SPMS): Secondary Progressive MS; (SCNT):
Somatic Cell Nuclear Transfer; (SCLC): Small Cell Lung Carcinoma; (SC): Stem
Cell; (SCOC): Stem Cell Oversight Committee; (SF): Synovial Fluid; (SLE):
Systemic Lupus Erythematosus; (SSc): Systemic Sclerosis; (UCE): Umbilical
Cord Epithelium; (UCB): Umbilical Cord Blood; (UC-HS): Umbilical Cord
Hematopoietic; (UC-MS): Umbilical Cord Mesenchymal; (VOD): Veno-
Occlusive Disease;
Aknowledgements
This review was not supported by grants. The authors hereby certify that all
work contained in this review is original work of DL, TI and BP. All the
information taken from other articles, including tables and pictures, have
been referenced in the “Bibliography” section. The authors claim full
responsibility for the contents of the article.
Author details
1Department of Nephrology, Dialysis and Transplantation, University of
Modena and Reggio Emilia Medical School, Modena, Italy.
2Department of
Biological and Biomedical Sciences, Glasgow Caledonian University, Glasgow,
UK.
3Department of General Surgery and Surgical Specialties, University of
Modena and Reggio Emilia Medical School, Surgical Clinic, Modena, Italy.
Authors’ contributions
The authors, namely DL, TI and BP, contributed equally to this work. All
authors read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 26 October 2010 Accepted: 17 January 2011
Published: 17 January 2011
References
1. Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD,
Moorman MA, Simonetti DW, Craig S, Marshak DR: Multilineage potential
of adult human mesenchymal stem cells. Science 1999,
284(5411):143-147.
2. Mayhall EA, Paffett-Lugassy N, Zon LI: The clinical potential of stem cells.
Curr Opin Cell Biol 2004, 16(6):713-720.
3. Fortier LA: Stem cells: classifications, controversies, and clinical
applications. Vet Surg 2005, 34(5):415-423.
4. Zhong W: Timing cell-fate determination during asymmetric cell
divisions. Curr Opin Neurobiol 2008, 18(5):472-478.
5. Doe CQ: Neural stem cells: balancing self-renewal with differentiation.
Development 2008, 135(9):1575-1587.
6. Knoblich JA: Mechanisms of asymmetric stem cell division. Cell 2008,
132(4):583-597.
7. Zhong W, Chia W: Neurogenesis and asymmetric cell division. Curr Opin
Neurobiol 2008, 18(1):4-11.
8. Baksh D, Song L, Tuan RS: Adult mesenchymal stem cells:
characterization, differentiation, and application in cell and gene
therapy. J Cell Mol Med 2004, 8(3):301-316.
9. Barry FP, Murphy JM: Mesenchymal stem cells: clinical applications and
biological characterization. Int J Biochem Cell Biol 2004, 36(4):568-584.
10. Thomson JA, Itskovitz-Eldor J, Shapiro SS, Waknitz MA, Swiergiel JJ,
Marshall VS, Jones JM: Embryonic stem cell lines derived from human
blastocysts. Science 1998, 282(5391):1145-1147.
11. Baharvand H, Ashtiani SK, Valojerdi MR, Shahverdi A, Taee A, Sabour D:
Establishment and in vitro differentiation of a new embryonic stem cell
line from human blastocyst. Differentiation 2004, 72(5):224-229.
12. Ladurner P, Rieger R, Baguna J: Spatial distribution and differentiation
potential of stem cells in hatchlings and adults in the marine
platyhelminth macrostomum sp.: a bromodeoxyuridine analysis. Dev Biol
2000, 226(2):231-241.
13. Fang TC, Alison MR, Wright NA, Poulsom R: Adult stem cell plasticity: will
engineered tissues be rejected? Int J Exp Pathol 2004, 85(3):115-124.
14. Pera MF, Reubinoff B, Trounson A: Human embryonic stem cells. J Cell Sci
2000, 113(Pt 1):5-10.
15. Pessina A, Gribaldo L: The key role of adult stem cells: therapeutic
perspectives. Curr Med Res Opin 2006, 22(11):2287-2300.
16. Gucciardo L, Lories R, Ochsenbein-Kolble N, Done E, Zwijsen A, Deprest J:
Fetal mesenchymal stem cells: isolation, properties and potential use in
perinatology and regenerative medicine. BJOG 2009, 116(2):166-172.
17. Blau HM, Brazelton TR, Weimann JM: The evolving concept of a stem cell:
entity or function? Cell 2001, 105(7):829-841.
Lodi et al. Journal of Experimental & Clinical Cancer Research 2011, 30:9
http://www.jeccr.com/content/30/1/9
Page 13 of 2018. Joshi D, Behari M: Neuronal stem cells. Neurol India 2003, 51(3):323-328.
19. Fan J, Varshney RR, Ren L, Cai D, Wang DA: Synovium-derived
mesenchymal stem cells: a new cell source for musculoskeletal
regeneration. Tissue Eng Part B Rev 2009, 15(1):75-86.
20. Voltarelli JC, Couri CE, Stracieri AB, Oliveira MC, Moraes DA, Pieroni F,
Coutinho M, Malmegrim KC, Foss-Freitas MC, Simoes BP, et al: Autologous
nonmyeloablative hematopoietic stem cell transplantation in newly
diagnosed type 1 diabetes mellitus. JAMA 2007, 297(14):1568-1576.
21. Sangwan VS, Fernandes M, Bansal AK, Vemuganti GK, Rao GN: Early results
of penetrating keratoplasty following limbal stem cell transplantation.
Indian J Ophthalmol 2005, 53(1):31-35.
22. Rosa SB, Voltarelli JC, Chies JA, Pranke P: The use of stem cells for the
treatment of autoimmune diseases. Braz J Med Biol Res 2007,
40(12):1579-1597.
23. Kallis YN, Alison MR, Forbes SJ: Bone marrow stem cells and liver disease.
Gut 2007, 56(5):716-724.
24. Varanou A, Page CP, Minger SL: Human embryonic stem cells and lung
regeneration. Br J Pharmacol 2008, 155(3):316-325.
25. Nieto Y, Jones RB, Shpall EJ: Stem-cell transplantation for the treatment
of advanced solid tumors. Springer Semin Immunopathol 2004, 26(1-
2):31-56.
26. Filip S, Mokry J, Horacek J, English D: Stem cells and the phenomena of
plasticity and diversity: a limiting property of carcinogenesis. Stem Cells
Dev 2008, 17(6):1031-1038.
27. Vicente-Duenas C, Gutierrez de Diego J, Rodriguez FD, Jimenez R,
Cobaleda C: The role of cellular plasticity in cancer development. Curr
Med Chem 2009, 16(28):3676-3685.
28. Reddy P, Arora M, Guimond M, Mackall CL: GVHD: a continuing barrier to
the safety of allogeneic transplantation. Biol Blood Marrow Transplant
2009, 15(1 Suppl):162-168.
29. Zarzeczny A, Caulfield T: Emerging ethical, legal and social issues
associated with stem cell research & and the current role of the moral
status of the embryo. Stem Cell Rev 2009, 5(2):96-101.
30. Wobus AM, Boheler KR: Embryonic stem cells: prospects for
developmental biology and cell therapy. Physiol Rev 2005, 85(2):635-678.
31. Oligny LL: Human molecular embryogenesis: an overview. Pediatr Dev
Pathol 2001, 4(4):324-343.
32. Talbot NC, Powell AM, Rexroad CE Jr: In vitro pluripotency of epiblasts
derived from bovine blastocysts. Mol Reprod Dev 1995, 42(1):35-52.
33. Odorico JS, Kaufman DS, Thomson JA: Multilineage differentiation from
human embryonic stem cell lines. Stem Cells 2001, 19(3):193-204.
34. Sjogren A, Hardarson T, Andersson K, Caisander G, Lundquist M, Wikland M,
Semb H, Hamberger L: Human blastocysts for the development of
embryonic stem cells. Reprod Biomed Online 2004, 9(3):326-329.
35. Cowan CA, Klimanskaya I, McMahon J, Atienza J, Witmyer J, Zucker JP,
Wang S, Morton CC, McMahon AP, Powers D, et al: Derivation of
embryonic stem-cell lines from human blastocysts. N Engl J Med 2004,
350(13):1353-1356.
36. Rosler ES, Fisk GJ, Ares X, Irving J, Miura T, Rao MS, Carpenter MK: Long-
term culture of human embryonic stem cells in feeder-free conditions.
Dev Dyn 2004, 229(2):259-274.
37. Fujioka T, Yasuchika K, Nakamura Y, Nakatsuji N, Suemori H: A simple and
efficient cryopreservation method for primate embryonic stem cells. Int J
Dev Biol 2004, 48(10):1149-1154.
38. Zhou CQ, Mai QY, Li T, Zhuang GL: Cryopreservation of human embryonic
stem cells by vitrification. Chin Med J (Engl) 2004, 117(7):1050-1055.
39. Reubinoff BE, Pera MF, Vajta G, Trounson AO: Effective cryopreservation of
human embryonic stem cells by the open pulled straw vitrification
method. Hum Reprod 2001, 16(10):2187-2194.
40. Hayflick L, Moorhead PS: The serial cultivation of human diploid cell
strains. Exp Cell Res 1961, 25:585-621.
41. Campisi J: From cells to organisms: can we learn about aging from cells
in culture? Exp Gerontol 2001, 36(4-6):607-618.
42. Wright WE, Shay JW: Historical claims and current interpretations of
replicative aging. Nat Biotechnol 2002, 20(7):682-688.
43. D’Ippolito G, Schiller PC, Ricordi C, Roos BA, Howard GA: Age-related
osteogenic potential of mesenchymal stromal stem cells from human
vertebral bone marrow. J Bone Miner Res 1999, 14(7):1115-1122.
44. Brook FA, Gardner RL: The origin and efficient derivation of embryonic
stem cells in the mouse. Proc Natl Acad Sci USA 1997, 94(11):5709-5712.
45. O’Donoghue K, Fisk NM: Fetal stem cells. Best Pract Res Clin Obstet
Gynaecol 2004, 18(6):853-875.
46. Gallacher L, Murdoch B, Wu D, Karanu F, Fellows F, Bhatia M: Identification
of novel circulating human embryonic blood stem cells. Blood 2000,
96(5):1740-1747.
47. Fortier LA, Nixon AJ, Williams J, Cable CS: Isolation and chondrocytic
differentiation of equine bone marrow-derived mesenchymal stem cells.
Am J Vet Res 1998, 59(9):1182-1187.
48. Deasy BM, Li Y, Huard J: Tissue engineering with muscle-derived stem
cells. Curr Opin Biotechnol 2004, 15(5):419-423.
49. Zuk PA, Zhu M, Mizuno H, Huang J, Futrell JW, Katz AJ, Benhaim P,
Lorenz HP, Hedrick MH: Multilineage cells from human adipose tissue:
implications for cell-based therapies. Tissue Eng 2001, 7(2):211-228.
50. De Bari C, Dell’Accio F, Tylzanowski P, Luyten FP: Multipotent
mesenchymal stem cells from adult human synovial membrane. Arthritis
Rheum 2001, 44(8):1928-1942.
51. Zarnett R, Salter RB: Periosteal neochondrogenesis for biologically
resurfacing joints: its cellular origin. Can J Surg 1989, 32(3):171-174.
52. Wong MH: Regulation of intestinal stem cells. J Investig Dermatol Symp
Proc 2004, 9(3):224-228.
53. Blanpain C, Lowry WE, Geoghegan A, Polak L, Fuchs E: Self-renewal,
multipotency, and the existence of two cell populations within an
epithelial stem cell niche. Cell 2004, 118(5):635-648.
54. Miura M, Gronthos S, Zhao M, Lu B, Fisher LW, Robey PG, Shi S: SHED: stem
cells from human exfoliated deciduous teeth. Proc Natl Acad Sci USA
2003, 100(10):5807-5812.
55. McKay RD: Stem cell biology and neurodegenerative disease. Philos Trans
R Soc Lond B Biol Sci 2004, 359(1445):851-856.
56. Young HE, Ceballos EM, Smith JC, Mancini ML, Wright RP, Ragan BL,
Bushell I, Lucas PA: Pluripotent mesenchymal stem cells reside within
avian connective tissue matrices. In Vitro Cell Dev Biol Anim 1993,
29A(9):723-736.
57. Smart N, Riley PR: The stem cell movement. Circ Res 2008,
102(10):1155-1168.
58. Behrstock S, Ebert AD, Klein S, Schmitt M, Moore JM, Svendsen CN: Lesion-
induced increase in survival and migration of human neural progenitor
cells releasing GDNF. Cell Transplant 2008, 17(7):753-762.
59. Wognum AW, Eaves AC, Thomas TE: Identification and isolation of
hematopoietic stem cells. Arch Med Res 2003, 34(6):461-475.
60. van Bekkum DW: Bone marrow transplantation. Transplant Proc 1977,
9(1):147-154.
61. Mimeault M, Batra SK: Recent progress on tissue-resident adult stem cell
biology and their therapeutic implications. Stem Cell Rev 2008, 4(1):27-49.
62. Chen FH, Rousche KT, Tuan RS: Technology Insight: adult stem cells in
cartilage regeneration and tissue engineering. Nat Clin Pract Rheumatol
2006, 2(7):373-382.
63. Bianco P, Robey PG, Simmons PJ: Mesenchymal stem cells: revisiting
history, concepts, and assays. Cell Stem Cell 2008, 2(4):313-319.
64. Menicanin D, Bartold PM, Zannettino AC, Gronthos S: Genomic profiling of
mesenchymal stem cells. Stem Cell Rev 2009, 5(1):36-50.
65. Alison MR, Poulsom R, Jeffery R, Dhillon AP, Quaglia A, Jacob J, Novelli M,
Prentice G, Williamson J, Wright NA: Hepatocytes from non-hepatic adult
stem cells. Nature 2000, 406(6793):257.
66. Ortiz LA, Gambelli F, McBride C, Gaupp D, Baddoo M, Kaminski N,
Phinney DG: Mesenchymal stem cell engraftment in lung is enhanced in
response to bleomycin exposure and ameliorates its fibrotic effects. Proc
Natl Acad Sci USA 2003, 100(14):8407-8411.
67. Brazelton TR, Rossi FM, Keshet GI, Blau HM: From marrow to brain:
expression of neuronal phenotypes in adult mice. Science 2000,
290(5497):1775-1779.
68. Chen FH, Tuan RS: Mesenchymal stem cells in arthritic diseases. Arthritis
Res Ther 2008, 10(5):223.
69. Tan SC, Pan WX, Ma G, Cai N, Leong KW, Liao K: Viscoelastic behaviour of
human mesenchymal stem cells. BMC Cell Biol 2008, 9:40.
70. Boquest AC, Noer A, Collas P: Epigenetic programming of mesenchymal
stem cells from human adipose tissue. Stem Cell Rev 2006, 2(4):319-329.
71. Mizuno H: Adipose-derived stem cells for tissue repair and regeneration: ten
years of research and a literature review. J Nippon Med Sch 2009, 76(2):56-66.
72. Meirelles Lda S, Nardi NB: Methodology, biology and clinical applications
of mesenchymal stem cells. Front Biosci 2009, 14:4281-4298.
Lodi et al. Journal of Experimental & Clinical Cancer Research 2011, 30:9
http://www.jeccr.com/content/30/1/9
Page 14 of 2073. Ruhil S, Kumar V, Rathee P: Umbilical cord stem cell: an overview. Curr
Pharm Biotechnol 2009, 10(3):327-334.
74. Mizoguchi M, Ikeda S, Suga Y, Ogawa H: Expression of cytokeratins and
cornified cell envelope-associated proteins in umbilical cord epithelium:
a comparative study of the umbilical cord, amniotic epithelia and fetal
skin. J Invest Dermatol 2000, 115(1):133-134.
75. Hoyes AD: Ultrastructure of the epithelium of the human umbilical cord.
J Anat 1969, 105(Pt 1):149-162.
76. Mizoguchi M, Suga Y, Sanmano B, Ikeda S, Ogawa H: Organotypic culture
and surface plantation using umbilical cord epithelial cells:
morphogenesis and expression of differentiation markers mimicking
cutaneous epidermis. J Dermatol Sci 2004, 35(3):199-206.
77. Sanmano B, Mizoguchi M, Suga Y, Ikeda S, Ogawa H: Engraftment of
umbilical cord epithelial cells in athymic mice: in an attempt to improve
reconstructed skin equivalents used as epithelial composite. J Dermatol
Sci 2005, 37(1):29-39.
78. Ruetze M, Gallinat S, Lim IJ, Chow E, Phan TT, Staeb F, Wenck H,
Deppert W, Knott A: Common features of umbilical cord epithelial cells
and epidermal keratinocytes. J Dermatol Sci 2008, 50(3):227-231.
79. Mihu CM, Mihu D, Costin N, Rus Ciuca D, Susman S, Ciortea R: Isolation
and characterization of stem cells from the placenta and the umbilical
cord. Rom J Morphol Embryol 2008, 49(4):441-446.
80. In ‘t Anker PS, Scherjon SA, Kleijburg-van der Keur C, de Groot-Swings GM,
Claas FH, Fibbe WE, Kanhai HH: Isolation of mesenchymal stem cells of
fetal or maternal origin from human placenta. Stem Cells 2004,
22(7):1338-1345.
81. Chien JW, Duncan S, Williams KM, Pavletic SZ: Bronchiolitis Obliterans
Syndrome After Allogeneic Hematopoietic Stem Cell Transplantation -
An Increasingly Recognized Manifestation of Chronic Graft-versus-Host
Disease. Biol Blood Marrow Transplant 2010, 16(1 Suppl):S106-14.
82. Moghadam KG, Marghoob B, Alimoghadam K, Shirani S, Ghavamzadeh A:
Bronchiolitis obliterans following hematopoietic stem cell
transplantation. Hematol Oncol Stem Cell Ther 2010, 3(2):100-101.
83. Miyagawa-Hayashino A, Sonobe M, Kubo T, Yoshizawa A, Date H,
Manabe T: Non-specific interstitial pneumonia as a manifestation of
graft-versus-host disease following pediatric allogeneic hematopoietic
stem cell transplantation. Pathol Int 2010, 60(2):137-142.
84. Bryant DH: Obliterative bronchiolitis in haematopoietic stem cell
transplantation: can it be treated? Eur Respir J 2005, 25(3):402-404.
85. Park M, Koh KN, Kim BE, Im HJ, Seo JJ: Clinical features of late onset non-
infectious pulmonary complications following pediatric allogeneic
hematopoietic stem cell transplantation. Clin Transplant 2010.
86. Yoshihara S, Yanik G, Cooke KR, Mineishi S: Bronchiolitis obliterans
syndrome (BOS), bronchiolitis obliterans organizing pneumonia (BOOP),
and other late-onset noninfectious pulmonary complications following
allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow
Transplant 2007, 13(7):749-759.
87. Majeski EI, Paintlia MK, Lopez AD, Harley RA, London SD, London L:
Respiratory reovirus 1/L induction of intraluminal fibrosis, a model of
bronchiolitis obliterans organizing pneumonia, is dependent on T
lymphocytes. Am J Pathol 2003, 163(4):1467-1479.
88. Ditschkowski M, Elmaagacli AH, Trenschel R, Peceny R, Koldehoff M,
Schulte C, Beelen DW: T-cell depletion prevents from bronchiolitis
obliterans and bronchiolitis obliterans with organizing pneumonia after
allogeneic hematopoietic stem cell transplantation with related donors.
Haematologica 2007, 92(4):558-561.
89. Kanda Y, Takahashi T, Imai Y, Miyagawa K, Ohishi N, Oka T, Chiba S, Hirai H,
Yazaki Y: Bronchiolitis obliterans organizing pneumonia after syngeneic
bone marrow transplantation for acute lymphoblastic leukemia. Bone
Marrow Transplant 1997, 19(12):1251-1253.
90. Cordier JF: Bronchiolitis obliterans organizing pneumonia. Semin Respir
Crit Care Med 2000, 21(2):135-146.
91. Patriarca F, Skert C, Bonifazi F, Sperotto A, Fili C, Stanzani M, Zaja F,
Cerno M, Geromin A, Bandini G, et al: Effect on survival of the
development of late-onset non-infectious pulmonary complications after
stem cell transplantation. Haematologica 2006, 91(9):1268-1272.
92. Ferrara JL, Levine JE, Reddy P, Holler E: Graft-versus-host disease. Lancet
2009, 373(9674):1550-1561.
93. Ferrara JL, Deeg HJ: Graft-versus-host disease. N Engl J Med 1991,
324(10):667-674.
94. Goker H, Haznedaroglu IC, Chao NJ: Acute graft-vs-host disease:
pathobiology and management. Exp Hematol 2001, 29(3):259-277.
95. Nevo S, Enger C, Swan V, Wojno KJ, Fuller AK, Altomonte V, Braine HG,
Noga SJ, Vogelsang GB: Acute bleeding after allogeneic bone marrow
transplantation: association with graft versus host disease and effect on
survival. Transplantation 1999, 67(5):681-689.
96. Fujii N, Takenaka K, Shinagawa K, Ikeda K, Maeda Y, Sunami K, Hiramatsu Y,
Matsuo K, Ishimaru F, Niiya K, et al: Hepatic graft-versus-host disease
presenting as an acute hepatitis after allogeneic peripheral blood stem
cell transplantation. Bone Marrow Transplant 2001, 27(9):1007-1010.
97. Lee JW, Joachim Deeg H: Prevention of chronic GVHD. Best Pract Res Clin
Haematol 2008, 21(2):259-270.
98. Lee SJ: New approaches for preventing and treating chronic graft-
versus-host disease. Blood 2005, 105(11):4200-4206.
99. Martin PJ, Weisdorf D, Przepiorka D, Hirschfeld S, Farrell A, Rizzo JD, Foley R,
Socie G, Carter S, Couriel D, et al: National Institutes of Health Consensus
Development Project on Criteria for Clinical Trials in Chronic Graft-
versus-Host Disease: VI. Design of Clinical Trials Working Group report.
Biol Blood Marrow Transplant 2006, 12(5):491-505.
100. Rimkus C: Acute complications of stem cell transplant. Semin Oncol Nurs
2009, 25(2):129-138.
101. Tabbara IA, Zimmerman K, Morgan C, Nahleh Z: Allogeneic hematopoietic
stem cell transplantation: complications and results. Arch Intern Med
2002, 162(14):1558-1566.
102. Skotnicki AB, Krawczyk J: Veno-occlusive disease–an important
complication in hematopoietic cells transplantation. Przegl Lek 2001,
58(11):995-999.
103. Lee SH, Yoo KH, Sung KW, Koo HH, Kwon YJ, Kwon MM, Park HJ, Park BK,
Kim YY, Park JA, et al: Hepatic veno-occlusive disease in children after
hematopoietic stem cell transplantation: incidence, risk factors, and
outcome. Bone Marrow Transplant 2010, 45(8):1287-1293.
104. Cesaro S, Pillon M, Talenti E, Toffolutti T, Calore E, Tridello G, Strugo L,
Destro R, Gazzola MV, Varotto S, et al: A prospective survey on incidence,
risk factors and therapy of hepatic veno-occlusive disease in children
after hematopoietic stem cell transplantation. Haematologica 2005,
90(10):1396-1404.
105. Shah MS, Jeevangi NK, Joshi A, Khattry N: Late-onset hepatic veno-
occlusive disease post autologous peripheral stem cell transplantation
successfully treated with oral defibrotide. J Cancer Res Ther 2009,
5(4):312-314.
106. Lakshminarayanan S, Sahdev I, Goyal M, Vlachos A, Atlas M, Lipton JM: Low
incidence of hepatic veno-occlusive disease in pediatric patients
undergoing hematopoietic stem cell transplantation attributed to a
combination of intravenous heparin, oral glutamine, and ursodiol at a
single transplant institution. Pediatr Transplant 2010, 14(5):618-621.
107. Pittenger MF, Martin BJ: Mesenchymal stem cells and their potential as
cardiac therapeutics. Circ Res 2004, 95(1):9-20.
108. Di Nicola M, Carlo-Stella C, Magni M, Milanesi M, Longoni PD, Matteucci P,
Grisanti S, Gianni AM: Human bone marrow stromal cells suppress T-
lymphocyte proliferation induced by cellular or nonspecific mitogenic
stimuli. Blood 2002, 99(10):3838-3843.
109. Alberio R, Campbell KH, Johnson AD: Reprogramming somatic cells into
stem cells. Reproduction 2006, 132(5):709-720.
110. Fairchild PJ, Cartland S, Nolan KF, Waldmann H: Embryonic stem cells and
the challenge of transplantation tolerance. Trends Immunol 2004,
25(9):465-470.
111. Amariglio N, Hirshberg A, Scheithauer BW, Cohen Y, Loewenthal R,
Trakhtenbrot L, Paz N, Koren-Michowitz M, Waldman D, Leider-Trejo L, et al:
Donor-derived brain tumor following neural stem cell transplantation in
an ataxia telangiectasia patient. PLoS Med 2009, 6(2):e1000029.
112. Lindvall O, Kokaia Z: Stem cells for the treatment of neurological
disorders. Nature 2006, 441(7097):1094-1096.
113. Lindvall O, Kokaia Z, Martinez-Serrano A: Stem cell therapy for human
neurodegenerative disorders-how to make it work. Nat Med 2004, 10
Suppl:S42-50.
114. Bjorklund LM, Sanchez-Pernaute R, Chung S, Andersson T, Chen IY,
McNaught KS, Brownell AL, Jenkins BG, Wahlestedt C, Kim KS, et al:
Embryonic stem cells develop into functional dopaminergic neurons
after transplantation in a Parkinson rat model. Proc Natl Acad Sci USA
2002, 99(4):2344-2349.
Lodi et al. Journal of Experimental & Clinical Cancer Research 2011, 30:9
http://www.jeccr.com/content/30/1/9
Page 15 of 20115. Arnhold S, Lenartz D, Kruttwig K, Klinz FJ, Kolossov E, Hescheler J, Sturm V,
Andressen C, Addicks K: Differentiation of green fluorescent protein-
labeled embryonic stem cell-derived neural precursor cells into Thy-1-
positive neurons and glia after transplantation into adult rat striatum. J
Neurosurg 2000, 93(6):1026-1032.
116. Werbowetski-Ogilvie TE, Bosse M, Stewart M, Schnerch A, Ramos-Mejia V,
Rouleau A, Wynder T, Smith MJ, Dingwall S, Carter T, et al: Characterization
of human embryonic stem cells with features of neoplastic progression.
Nat Biotechnol 2009, 27(1):91-97.
117. Crooks VA, Snyder J: Regulating medical tourism. Lancet 2010,
376(9751):1465-1466.
118. Barclay E: Stem-cell experts raise concerns about medical tourism. Lancet
2009, 373(9667):883-884.
119. Lau D, Ogbogu U, Taylor B, Stafinski T, Menon D, Caulfield T: Stem cell
clinics online: the direct-to-consumer portrayal of stem cell medicine.
Cell Stem Cell 2008, 3(6):591-594.
120. Pepper MS: Cell-based therapy - navigating troubled waters. S Afr Med J
2010, 100(5):286, 288.
121. Woo P: Systemic juvenile idiopathic arthritis: diagnosis, management,
and outcome. Nat Clin Pract Rheumatol 2006, 2(1):28-34.
122. Ringe J, Sittinger M: Tissue engineering in the rheumatic diseases. Arthritis
Res Ther 2009, 11(1):211.
123. Hayward K, Wallace CA: Recent developments in anti-rheumatic drugs in
pediatrics: treatment of juvenile idiopathic arthritis. Arthritis Res Ther 2009,
11(1):216.
124. Snowden JA, Passweg J, Moore JJ, Milliken S, Cannell P, Van Laar J,
Verburg R, Szer J, Taylor K, Joske D, et al: Autologous hemopoietic stem
cell transplantation in severe rheumatoid arthritis: a report from the
EBMT and ABMTR. J Rheumatol 2004, 31(3):482-488.
125. Moore J, Brooks P, Milliken S, Biggs J, Ma D, Handel M, Cannell P, Will R,
Rule S, Joske D, et al: A pilot randomized trial comparing CD34-selected
versus unmanipulated hemopoietic stem cell transplantation for severe,
refractory rheumatoid arthritis. Arthritis Rheum 2002, 46(9):2301-2309.
126. De Kleer IM, Brinkman DM, Ferster A, Abinun M, Quartier P, Van Der Net J,
Ten Cate R, Wedderburn LR, Horneff G, Oppermann J, et al: Autologous
stem cell transplantation for refractory juvenile idiopathic arthritis:
analysis of clinical effects, mortality, and transplant related morbidity.
Ann Rheum Dis 2004, 63(10):1318-1326.
127. Jallouli M, Frigui M, Hmida MB, Marzouk S, Kaddour N, Bahloul Z: Clinical
and immunological manifestations of systemic lupus erythematosus:
study on 146 south Tunisian patients. Saudi J Kidney Dis Transpl 2008,
19(6):1001-1008.
128. Ioannou Y, Isenberg DA: Current concepts for the management of
systemic lupus erythematosus in adults: a therapeutic challenge.
Postgrad Med J 2002, 78(924):599-606.
129. Traynor AE, Barr WG, Rosa RM, Rodriguez J, Oyama Y, Baker S, Brush M,
Burt RK: Hematopoietic stem cell transplantation for severe and
refractory lupus. Analysis after five years and fifteen patients. Arthritis
Rheum 2002, 46(11):2917-2923.
130. Burt RK, Traynor A, Statkute L, Barr WG, Rosa R, Schroeder J, Verda L,
Krosnjar N, Quigley K, Yaung K, et al: Nonmyeloablative hematopoietic
stem cell transplantation for systemic lupus erythematosus. JAMA 2006,
295(5):527-535.
131. Goldblatt F, Isenberg DA: New therapies for systemic lupus
erythematosus. Clin Exp Immunol 2005, 140(2):205-212.
132. Compston A, Coles A: Multiple sclerosis. Lancet 2008, 372(9648):1502-1517.
133. Katsara M, Matsoukas J, Deraos G, Apostolopoulos V: Towards
immunotherapeutic drugs and vaccines against multiple sclerosis. Acta
Biochim Biophys Sin (Shanghai) 2008, 40(7):636-642.
134. Ebers GC: Natural history of primary progressive multiple sclerosis. Mult
Scler 2004, 10(Suppl 1):S8-13, discussion S13-15.
135. Saccardi R, Mancardi GL, Solari A, Bosi A, Bruzzi P, Di Bartolomeo P,
Donelli A, Filippi M, Guerrasio A, Gualandi F, et al: Autologous HSCT for
severe progressive multiple sclerosis in a multicenter trial: impact on
disease activity and quality of life. Blood 2005, 105(6):2601-2607.
136. Fassas A, Passweg JR, Anagnostopoulos A, Kazis A, Kozak T, Havrdova E,
Carreras E, Graus F, Kashyap A, Openshaw H, et al: Hematopoietic stem cell
transplantation for multiple sclerosis. A retrospective multicenter study.
J Neurol 2002, 249(8):1088-1097.
137. Fassas A, Anagnostopoulos A, Kazis A, Kapinas K, Sakellari I, Kimiskidis V,
Smias C, Eleftheriadis N, Tsimourtou V: Autologous stem cell
transplantation in progressive multiple sclerosis–an interim analysis of
efficacy. J Clin Immunol 2000, 20(1):24-30.
138. Mezey E, Chandross KJ, Harta G, Maki RA, McKercher SR: Turning blood
into brain: cells bearing neuronal antigens generated in vivo from bone
marrow. Science 2000, 290(5497):1779-1782.
139. Lim IG, Schrieber L: Management of systemic sclerosis. Isr Med Assoc J
2002, 4(11 Suppl):953-957.
140. Akerkar SM, Bichile LS: Therapeutic options for systemic sclerosis. Indian J
Dermatol Venereol Leprol 2004, 70(2):67-75.
141. Tyndall A, Black C, Finke J, Winkler J, Mertlesmann R, Peter HH, Gratwohl A:
Treatment of systemic sclerosis with autologous haemopoietic stem cell
transplantation. Lancet 1997, 349(9047):254.
142. van den Hoogen FH, van de Putte LB: Treatment of systemic sclerosis.
Curr Opin Rheumatol 1994, 6(6):637-641.
143. Martini A, Maccario R, Ravelli A, Montagna D, De Benedetti F, Bonetti F,
Viola S, Zecca M, Perotti C, Locatelli F: Marked and sustained
improvement two years after autologous stem cell transplantation in a
girl with systemic sclerosis. Arthritis Rheum 1999, 42(4):807-811.
144. Binks M, Passweg JR, Furst D, McSweeney P, Sullivan K, Besenthal C,
Finke J, Peter HH, van Laar J, Breedveld FC, et al: Phase I/II trial of
autologous stem cell transplantation in systemic sclerosis: procedure
related mortality and impact on skin disease. Ann Rheum Dis 2001,
60(6):577-584.
145. Farge D, Marolleau JP, Zohar S, Marjanovic Z, Cabane J, Mounier N,
Hachulla E, Philippe P, Sibilia J, Rabian C, et al: Autologous bone marrow
transplantation in the treatment of refractory systemic sclerosis: early
results from a French multicentre phase I-II study. Br J Haematol 2002,
119(3):726-739.
146. McSweeney PA, Nash RA, Sullivan KM, Storek J, Crofford LJ, Dansey R,
Mayes MD, McDonagh KT, Nelson JL, Gooley TA, et al: High-dose
immunosuppressive therapy for severe systemic sclerosis: initial
outcomes. Blood 2002, 100(5):1602-1610.
147. Farge D, Passweg J, van Laar JM, Marjanovic Z, Besenthal C, Finke J,
Peter HH, Breedveld FC, Fibbe WE, Black C, et al: Autologous stem cell
transplantation in the treatment of systemic sclerosis: report from the
EBMT/EULAR Registry. Ann Rheum Dis 2004, 63(8):974-981.
148. Rampton DS: Management of Crohn’s disease. BMJ 1999,
319(7223):1480-1485.
149. Cassinotti A, Annaloro C, Ardizzone S, Onida F, Della Volpe A, Clerici M,
Usardi P, Greco S, Maconi G, Porro GB, et al: Autologous haematopoietic
stem cell transplantation without CD34+ cell selection in refractory
Crohn’s disease. Gut 2008, 57(2):211-217.
150. Oyama Y, Craig RM, Traynor AE, Quigley K, Statkute L, Halverson A, Brush M,
Verda L, Kowalska B, Krosnjar N, et al: Autologous hematopoietic stem cell
transplantation in patients with refractory Crohn’s disease.
Gastroenterology 2005, 128(3):552-563.
151. Burt RK, Traynor A, Oyama Y, Craig R: High-dose immune suppression and
autologous hematopoietic stem cell transplantation in refractory Crohn
disease. Blood 2003, 101(5):2064-2066.
152. Stasi R, Provan D: Management of immune thrombocytopenic purpura in
adults. Mayo Clin Proc 2004, 79(4):504-522.
153. Huhn RD, Fogarty PF, Nakamura R, Read EJ, Leitman SF, Rick ME, Kimball J,
Greene A, Hansmann K, Gratwohl A, et al: High-dose cyclophosphamide
with autologous lymphocyte-depleted peripheral blood stem cell (PBSC)
support for treatment of refractory chronic autoimmune
thrombocytopenia. Blood 2003, 101(1):71-77.
154. Urban C, Lackner H, Sovinz P, Benesch M, Schwinger W, Dornbusch HJ,
Moser A: Successful unrelated cord blood transplantation in a 7-year-old
boy with Evans syndrome refractory to immunosuppression and double
autologous stem cell transplantation. Eur J Haematol 2006, 76(6):526-530.
155. Riechsteiner G, Speich R, Schanz U, Russi EW, Weder W, Boehler A:
Haemolytic anaemia after lung transplantation: an immune-mediated
phenomenon? Swiss Med Wkly 2003, 133(9-10):143-147.
156. Pratt G, Kinsey SE: Remission of severe, intractable autoimmune
haemolytic anaemia following matched unrelated donor transplantation.
Bone Marrow Transplant 2001, 28(8):791-793.
157. Sallah S, Wan JY, Hanrahan LR: Future development of
lymphoproliferative disorders in patients with autoimmune hemolytic
anemia. Clin Cancer Res 2001, 7(4):791-794.
158. Seeliger S, Baumann M, Mohr M, Jurgens H, Frosch M, Vormoor J:
Autologous peripheral blood stem cell transplantation and anti-B-cell
Lodi et al. Journal of Experimental & Clinical Cancer Research 2011, 30:9
http://www.jeccr.com/content/30/1/9
Page 16 of 20directed immunotherapy for refractory auto-immune haemolytic
anaemia. Eur J Pediatr 2001, 160(8):492-496.
159. Passweg JR, Rabusin M, Musso M, Beguin Y, Cesaro S, Ehninger G,
Espigado I, Iriondo A, Jost L, Koza V, et al: Haematopoetic stem cell
transplantation for refractory autoimmune cytopenia. Br J Haematol 2004,
125(6):749-755.
160. Eisenbarth GS: Update in type 1 diabetes. J Clin Endocrinol Metab 2007,
92(7):2403-2407.
161. Aiello LP, Gardner TW, King GL, Blankenship G, Cavallerano JD, Ferris FL,
Klein R: Diabetic retinopathy. Diabetes Care 1998, 21(1):143-156.
162. Sima AA, Zhang W, Grunberger G: Type 1 diabetic neuropathy and C-
peptide. Exp Diabesity Res 2004, 5(1):65-77.
163. Ingberg CM, Palmer M, Schvarcz E, Aman J: Prevalence of urinary tract
symptoms in long-standing type 1 diabetes mellitus. Diabetes Metab
1998, 24(4):351-354.
164. Couri CE, Oliveira MC, Stracieri AB, Moraes DA, Pieroni F, Barros GM,
Madeira MI, Malmegrim KC, Foss-Freitas MC, Simoes BP, et al: C-peptide
levels and insulin independence following autologous nonmyeloablative
hematopoietic stem cell transplantation in newly diagnosed type 1
diabetes mellitus. JAMA 2009, 301(15):1573-1579.
165. Snarski E, Torosian T, Paluszewska M, Urbanowska E, Milczarczyk A,
Jedynasty K, Franek E, Jedrzejczak WW: Alleviation of exogenous insulin
requirement in type 1 diabetes mellitus after immunoablation and
transplantation of autologous hematopoietic stem cells. Pol Arch Med
Wewn 2009, 119(6):422-426.
166. Trivedi HL, Vanikar AV, Thakker U, Firoze A, Dave SD, Patel CN, Patel JV,
Bhargava AB, Shankar V: Human adipose tissue-derived mesenchymal
stem cells combined with hematopoietic stem cell transplantation
synthesize insulin. Transplant Proc 2008, 40(4):1135-1139.
167. Wijesekera LC, Leigh PN: Amyotrophic lateral sclerosis. Orphanet J Rare Dis
2009, 4:3.
168. Janson CG, Ramesh TM, During MJ, Leone P, Heywood J: Human
intrathecal transplantation of peripheral blood stem cells in amyotrophic
lateral sclerosis. J Hematother Stem Cell Res 2001, 10(6):913-915.
169. Mazzini L, Ferrero I, Luparello V, Rustichelli D, Gunetti M, Mareschi K, Testa L,
Stecco A, Tarletti R, Miglioretti M, et al: Mesenchymal stem cell
transplantation in amyotrophic lateral sclerosis: A Phase I clinical trial.
Exp Neurol 2010, 223(1):229-37.
170. Mazzini L, Fagioli F, Boccaletti R, Mareschi K, Oliveri G, Olivieri C, Pastore I,
Marasso R, Madon E: Stem cell therapy in amyotrophic lateral sclerosis: a
methodological approach in humans. Amyotroph Lateral Scler Other Motor
Neuron Disord 2003, 4(3):158-161.
171. Martinez HR, Gonzalez-Garza MT, Moreno-Cuevas JE, Caro E, Gutierrez-
Jimenez E, Segura JJ: Stem-cell transplantation into the frontal motor cortex
in amyotrophic lateral sclerosis patients. Cytotherapy 2009, 11(1):26-34.
172. Papadeas ST, Maragakis NJ: Advances in stem cell research for
Amyotrophic Lateral Sclerosis. Curr Opin Biotechnol 2009, 20(5):545-551.
173. Astradsson A, Cooper O, Vinuela A, Isacson O: Recent advances in cell-
based therapy for Parkinson disease. Neurosurg Focus 2008, 24(3-4):E6.
174. Weintraub D, Comella CL, Horn S: Parkinson’s disease–Part 2: Treatment
of motor symptoms. Am J Manag Care 2008, 14(2 Suppl):S49-58.
175. Hagell P, Schrag A, Piccini P, Jahanshahi M, Brown R, Rehncrona S,
Widner H, Brundin P, Rothwell JC, Odin P, et al: Sequential bilateral
transplantation in Parkinson’s disease: effects of the second graft. Brain
1999, 122(Pt 6):1121-1132.
176. Brundin P, Pogarell O, Hagell P, Piccini P, Widner H, Schrag A, Kupsch A,
Crabb L, Odin P, Gustavii B, et al: Bilateral caudate and putamen grafts of
embryonic mesencephalic tissue treated with lazaroids in Parkinson’s
disease. Brain 2000, 123(Pt 7):1380-1390.
177. Freed CR, Greene PE, Breeze RE, Tsai WY, DuMouchel W, Kao R, Dillon S,
Winfield H, Culver S, Trojanowski JQ, et al: Transplantation of embryonic
dopamine neurons for severe Parkinson’s disease. N Engl J Med 2001,
344(10):710-719.
178. Hauser RA, Freeman TB, Snow BJ, Nauert M, Gauger L, Kordower JH,
Olanow CW: Long-term evaluation of bilateral fetal nigral transplantation
in Parkinson disease. Arch Neurol 1999, 56(2):179-187.
179. Olanow CW, Goetz CG, Kordower JH, Stoessl AJ, Sossi V, Brin MF,
Shannon KM, Nauert GM, Perl DP, Godbold J, et al: A double-blind
controlled trial of bilateral fetal nigral transplantation in Parkinson’s
disease. Ann Neurol 2003, 54(3):403-414.
180. Lima C, Pratas-Vital J, Escada P, Hasse-Ferreira A, Capucho C, Peduzzi JD:
Olfactory mucosa autografts in human spinal cord injury: a pilot clinical
study. J Spinal Cord Med 2006, 29(3):191-203, discussion 204-196.
181. Mackay-Sim A, Feron F, Cochrane J, Bassingthwaighte L, Bayliss C, Davies W,
Fronek P, Gray C, Kerr G, Licina P, et al: Autologous olfactory ensheathing
cell transplantation in human paraplegia: a 3-year clinical trial. Brain
2008, 131(Pt 9):2376-2386.
182. Yoon SH, Shim YS, Park YH, Chung JK, Nam JH, Kim MO, Park HC, Park SR,
Min BH, Kim EY, et al: Complete spinal cord injury treatment using
autologous bone marrow cell transplantation and bone marrow
stimulation with granulocyte macrophage-colony stimulating factor:
Phase I/II clinical trial. Stem Cells 2007, 25(8):2066-2073.
183. Freeman TB, Cicchetti F, Hauser RA, Deacon TW, Li XJ, Hersch SM,
Nauert GM, Sanberg PR, Kordower JH, Saporta S, et al: Transplanted fetal
striatum in Huntington’s disease: phenotypic development and lack of
pathology. Proc Natl Acad Sci USA 2000, 97(25):13877-13882.
184. Kopyov OV, Jacques S, Lieberman A, Duma CM, Eagle KS: Safety of
intrastriatal neurotransplantation for Huntington’s disease patients. Exp
Neurol 1998, 149(1):97-108.
185. Rosser AE, Barker RA, Harrower T, Watts C, Farrington M, Ho AK,
Burnstein RM, Menon DK, Gillard JH, Pickard J, et al: Unilateral
transplantation of human primary fetal tissue in four patients with
Huntington’s disease: NEST-UK safety report ISRCTN no 36485475. J
Neurol Neurosurg Psychiatry 2002, 73(6):678-685.
186. Gaura V, Bachoud-Levi AC, Ribeiro MJ, Nguyen JP, Frouin V, Baudic S,
Brugieres P, Mangin JF, Boisse MF, Palfi S, et al: Striatal neural grafting
improves cortical metabolism in Huntington’s disease patients. Brain
2004, 127(Pt 1):65-72.
187. Palfi S, Nguyen JP, Brugieres P, Le Guerinel C, Hantraye P, Remy P,
Rostaing S, Defer GL, Cesaro P, Keravel Y, et al: MRI-stereotactical approach
for neural grafting in basal ganglia disorders. Exp Neurol 1998,
150(2):272-281.
188. Hauser RA, Sandberg PR, Freeman TB, Stoessl AJ: Bilateral human fetal
striatal transplantation in Huntington’s disease. Neurology 2002,
58(11):1704, author reply 1704.
189. Rabinovich SS, Seledtsov VI, Banul NV, Poveshchenko OV, Senyukov VV,
Astrakov SV, Samarin DM, Taraban VY: Cell therapy of brain stroke. Bull Exp
Biol Med 2005, 139(1):126-128.
190. Bang OY, Lee JS, Lee PH, Lee G: Autologous mesenchymal stem cell
transplantation in stroke patients. Ann Neurol 2005, 57(6):874-882.
191. Shyu WC, Lin SZ, Lee CC, Liu DD, Li H: Granulocyte colony-stimulating
factor for acute ischemic stroke: a randomized controlled trial. CMAJ
2006, 174(7):927-933.
192. Yiu EM, Kornberg AJ: Duchenne muscular dystrophy. Neurol India 2008,
56(3):236-247.
193. Torrente Y, Belicchi M, Marchesi C, Dantona G, Cogiamanian F, Pisati F,
Gavina M, Giordano R, Tonlorenzi R, Fagiolari G, et al: Autologous
transplantation of muscle-derived CD133+ stem cells in Duchenne
muscle patients. Cell Transplant 2007, 16(6):563-577.
194. Neumeyer AM, Cros D, McKenna-Yasek D, Zawadzka A, Hoffman EP,
Pegoraro E, Hunter RG, Munsat TL, Brown RH Jr: Pilot study of myoblast
transfer in the treatment of Becker muscular dystrophy. Neurology 1998,
51(2):589-592.
195. Gussoni E, Blau HM, Kunkel LM: The fate of individual myoblasts after
transplantation into muscles of DMD patients. Nat Med 1997,
3(9):970-977.
196. Miller RG, Sharma KR, Pavlath GK, Gussoni E, Mynhier M, Lanctot AM,
Greco CM, Steinman L, Blau HM: Myoblast implantation in Duchenne
muscular dystrophy: the San Francisco study. Muscle Nerve 1997,
20(4):469-478.
197. Mendell JR, Kissel JT, Amato AA, King W, Signore L, Prior TW, Sahenk Z,
Benson S, McAndrew PE, Rice R, et al: Myoblast transfer in the
treatment of Duchenne’s muscular dystrophy. NE n g lJM e d1995,
333(13):832-838.
198. Tremblay JP, Malouin F, Roy R, Huard J, Bouchard JP, Satoh A, Richards CL:
Results of a triple blind clinical study of myoblast transplantations
without immunosuppressive treatment in young boys with Duchenne
muscular dystrophy. Cell Transplant 1993, 2(2):99-112.
199. Vincent R: Advances in the early diagnosis and management of acute
myocardial infarction. J Accid Emerg Med 1996, 13(2):74-79.
Lodi et al. Journal of Experimental & Clinical Cancer Research 2011, 30:9
http://www.jeccr.com/content/30/1/9
Page 17 of 20200. Goldman LE, Eisenberg MJ: Identification and management of patients
with failed thrombolysis after acute myocardial infarction. Ann Intern Med
2000, 132(7):556-565.
201. Menasche P, Alfieri O, Janssens S, McKenna W, Reichenspurner H,
Trinquart L, Vilquin JT, Marolleau JP, Seymour B, Larghero J, et al: The
Myoblast Autologous Grafting in Ischemic Cardiomyopathy (MAGIC) trial:
first randomized placebo-controlled study of myoblast transplantation.
Circulation 2008, 117(9):1189-1200.
202. Hagege AA, Marolleau JP, Vilquin JT, Alheritiere A, Peyrard S, Duboc D,
Abergel E, Messas E, Mousseaux E, Schwartz K, et al: Skeletal myoblast
transplantation in ischemic heart failure: long-term follow-up of the first
phase I cohort of patients. Circulation 2006, 114(1 Suppl):I108-113.
203. Siminiak T, Kalawski R, Fiszer D, Jerzykowska O, Rzezniczak J,
Rozwadowska N, Kurpisz M: Autologous skeletal myoblast transplantation
for the treatment of postinfarction myocardial injury: phase I clinical
study with 12 months of follow-up. Am Heart J 2004, 148(3):531-537.
204. Schachinger V, Assmus B, Erbs S, Elsasser A, Haberbosch W, Hambrecht R,
Yu J, Corti R, Mathey DG, Hamm CW, et al: Intracoronary infusion of bone
marrow-derived mononuclear cells abrogates adverse left ventricular
remodelling post-acute myocardial infarction: insights from the
reinfusion of enriched progenitor cells and infarct remodelling in acute
myocardial infarction (REPAIR-AMI) trial. Eur J Heart Fail 2009,
11(10):973-979.
205. Schachinger V, Erbs S, Elsasser A, Haberbosch W, Hambrecht R,
Holschermann H, Yu J, Corti R, Mathey DG, Hamm CW, et al: Intracoronary
bone marrow-derived progenitor cells in acute myocardial infarction. N
Engl J Med 2006, 355(12):1210-1221.
206. Wollert KC, Meyer GP, Lotz J, Ringes-Lichtenberg S, Lippolt P,
Breidenbach C, Fichtner S, Korte T, Hornig B, Messinger D, et al:
Intracoronary autologous bone-marrow cell transfer after myocardial
infarction: the BOOST randomised controlled clinical trial. Lancet 2004,
364(9429):141-148.
207. Ang LP, Tan DT: Ocular surface stem cells and disease: current concepts
and clinical applications. Ann Acad Med Singapore 2004, 33(5):576-580.
208. Rama P, Bonini S, Lambiase A, Golisano O, Paterna P, De Luca M,
Pellegrini G: Autologous fibrin-cultured limbal stem cells permanently
restore the corneal surface of patients with total limbal stem cell
deficiency. Transplantation 2001, 72(9):1478-1485.
209. Daya SM, Ilari FA: Living related conjunctival limbal allograft for the
treatment of stem cell deficiency. Ophthalmology 2001, 108(1):126-133,
discussion 133-124.
210. Ilari L, Daya SM: Long-term outcomes of keratolimbal allograft for the
treatment of severe ocular surface disorders. Ophthalmology 2002,
109(7):1278-1284.
211. Solomon A, Ellies P, Anderson DF, Touhami A, Grueterich M, Espana EM,
Ti SE, Goto E, Feuer WJ, Tseng SC: Long-term outcome of keratolimbal
allograft with or without penetrating keratoplasty for total limbal stem
cell deficiency. Ophthalmology 2002, 109(6):1159-1166.
212. Shimazaki J, Maruyama F, Shimmura S, Fujishima H, Tsubota K:
Immunologic rejection of the central graft after limbal allograft
transplantation combined with penetrating keratoplasty. Cornea 2001,
20(2):149-152.
213. Mobasheri A, Csaki C, Clutterbuck AL, Rahmanzadeh M, Shakibaei M:
Mesenchymal stem cells in connective tissue engineering and
regenerative medicine: applications in cartilage repair and osteoarthritis
therapy. Histol Histopathol 2009, 24(3):347-366.
214. McNair PJ, Simmonds MA, Boocock MG, Larmer PJ: Exercise therapy for
the management of osteoarthritis of the hip joint: a systematic review.
Arthritis Res Ther 2009, 11(3):R98.
215. Srbely JZ: Ultrasound in the management of osteoarthritis: part I: a
review of the current literature. J Can Chiropr Assoc 2008, 52(1):30-37.
216. Barron MC, Rubin BR: Managing osteoarthritic knee pain. J Am Osteopath
Assoc 2007, 107(10 Suppl 6):ES21-27.
217. Santaguida PL, Hawker GA, Hudak PL, Glazier R, Mahomed NN, Kreder HJ,
Coyte PC, Wright JG: Patient characteristics affecting the prognosis of
total hip and knee joint arthroplasty: a systematic review. Can J Surg
2008, 51(6):428-436.
218. Centeno CJ, Busse D, Kisiday J, Keohan C, Freeman M, Karli D: Increased
knee cartilage volume in degenerative joint disease using
percutaneously implanted, autologous mesenchymal stem cells. Pain
Physician 2008, 11(3):343-353.
219. Schuppan D, Afdhal NH: Liver cirrhosis. Lancet 2008, 371(9615):838-851.
220. Pai M, Zacharoulis D, Milicevic MN, Helmy S, Jiao LR, Levicar N, Tait P,
Scott M, Marley SB, Jestice K, et al: Autologous infusion of expanded
mobilized adult bone marrow-derived CD34+ cells into patients with
alcoholic liver cirrhosis. Am J Gastroenterol 2008, 103(8):1952-1958.
221. Lyra AC, Soares MB, da Silva LF, Fortes MF, Silva AG, Mota AC, Oliveira SA,
Braga EL, de Carvalho WA, Genser B, et al: Feasibility and safety of
autologous bone marrow mononuclear cell transplantation in patients
with advanced chronic liver disease. World J Gastroenterol 2007,
13(7):1067-1073.
222. am Esch JS, Knoefel WT, Klein M, Ghodsizad A, Fuerst G, Poll LW,
Piechaczek C, Burchardt ER, Feifel N, Stoldt V, et al: Portal application of
autologous CD133+ bone marrow cells to the liver: a novel concept to
support hepatic regeneration. Stem Cells 2005, 23(4):463-470.
223. Terai S, Ishikawa T, Omori K, Aoyama K, Marumoto Y, Urata Y, Yokoyama Y,
Uchida K, Yamasaki T, Fujii Y, et al: Improved liver function in patients
with liver cirrhosis after autologous bone marrow cell infusion therapy.
Stem Cells 2006, 24(10):2292-2298.
224. Heldwein FL, McCullough TC, Souto CA, Galiano M, Barret E: Localized
renal cell carcinoma management: an update. Int Braz J Urol 2008,
34(6):676-689, discussion 689-690.
225. Oudard S, George D, Medioni J, Motzer R: Treatment options in renal cell
carcinoma: past, present and future. Ann Oncol 2007, 18(Suppl 10):x25-31.
226. Peccatori J, Barkholt L, Demirer T, Sormani MP, Bruzzi P, Ciceri F, Zambelli A,
Da Prada GA, Pedrazzoli P, Siena S, et al: Prognostic factors for survival in
patients with advanced renal cell carcinoma undergoing
nonmyeloablative allogeneic stem cell transplantation. Cancer 2005,
104(10):2099-2103.
227. Barkholt L, Bregni M, Remberger M, Blaise D, Peccatori J, Massenkeil G,
Pedrazzoli P, Zambelli A, Bay JO, Francois S, et al: Allogeneic
haematopoietic stem cell transplantation for metastatic renal carcinoma
in Europe. Ann Oncol 2006, 17(7):1134-1140.
228. Artz AS, Van Besien K, Zimmerman T, Gajewski TF, Rini BI, Hu HS,
Stadler WM, Vogelzang NJ: Long-term follow-up of nonmyeloablative
allogeneic stem cell transplantation for renal cell carcinoma: The
University of Chicago Experience. Bone Marrow Transplant 2005,
35(3):253-260.
229. Childs R, Chernoff A, Contentin N, Bahceci E, Schrump D, Leitman S,
Read EJ, Tisdale J, Dunbar C, Linehan WM, et al: Regression of metastatic
renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood
stem-cell transplantation. N Engl J Med 2000, 343(11):750-758.
230. Singletary SE: Breast cancer management: the road to today. Cancer 2008,
113(7 Suppl):1844-1849.
231. Biron P, Durand M, Roche H, Delozier T, Battista C, Fargeot P, Spaeth D,
Bachelot T, Poiget E, Monnot F, et al: Pegase 03: a prospective
randomized phase III trial of FEC with or without high-dose thiotepa,
cyclophosphamide and autologous stem cell transplantation in first-line
treatment of metastatic breast cancer. Bone Marrow Transplant 2008,
41(6):555-562.
232. Ueno NT, Rizzo JD, Demirer T, Cheng YC, Hegenbart U, Zhang MJ,
Bregni M, Carella A, Blaise D, Bashey A, et al: Allogeneic hematopoietic cell
transplantation for metastatic breast cancer. Bone Marrow Transplant
2008, 41(6):537-545.
233. Carella AM, Bregni M: Current role of allogeneic stem cell transplantation
in breast cancer. Ann Oncol 2007, 18(10):1591-1593.
234. Gill S, Blackstock AW, Goldberg RM: Colorectal cancer. Mayo Clin Proc 2007,
82(1):114-129.
235. Benson AB: Epidemiology, disease progression, and economic burden of
colorectal cancer. J Manag Care Pharm 2007, 13(6 Suppl C):S5-18.
236. Nagy VM: Updating the management of rectal cancer. J Gastrointestin
Liver Dis 2008, 17(1):69-74.
237. Kojima R, Kami M, Hori A, Murashige N, Ohnishi M, Kim SW, Hamaki T,
Kishi Y, Tsutsumi Y, Masauzi N, et al: Reduced-intensity allogeneic
hematopoietic stem-cell transplantation as an immunotherapy for
metastatic colorectal cancer. Transplantation 2004, 78(12):1740-1746.
238. Aglietta M, Barkholt L, Schianca FC, Caravelli D, Omazic B, Minotto C,
Leone F, Hentschke P, Bertoldero G, Capaldi A, et al: Reduced-intensity
allogeneic hematopoietic stem cell transplantation in metastatic
colorectal cancer as a novel adoptive cell therapy approach. The
European group for blood and marrow transplantation experience. Biol
Blood Marrow Transplant 2009, 15(3):326-335.
Lodi et al. Journal of Experimental & Clinical Cancer Research 2011, 30:9
http://www.jeccr.com/content/30/1/9
Page 18 of 20239. Hashino S, Kobayashi S, Takahata M, Onozawa M, Nakagawa M,
Kawamura T, Fujisawa F, Izumiyama K, Kahata K, Kondo T, et al: Graft-
versus-tumor effect after reduced-intensity allogeneic hematopoietic
stem cell transplantation in a patient with advanced colon cancer. Int J
Clin Oncol 2008, 13(2):176-180.
240. Carnevale-Schianca F, Cignetti A, Capaldi A, Vitaggio K, Vallario A,
Ricchiardi A, Sperti E, Ferraris R, Gatti M, Grignani G, et al: Allogeneic
nonmyeloablative hematopoietic cell transplantation in metastatic colon
cancer: tumor-specific T cells directed to a tumor-associated antigen are
generated in vivo during GVHD. Blood 2006, 107(9):3795-3803.
241. Schilder RJ, Boente MP, Corn BW, Lanciano RM, Young RC, Ozols RF: The
management of early ovarian cancer. Oncology (Williston Park) 1995,
9(2):171-182, discussion 185-177.
242. Bay JO, Fleury J, Choufi B, Tournilhac O, Vincent C, Bailly C, Dauplat J,
Viens P, Faucher C, Blaise D: Allogeneic hematopoietic stem cell
transplantation in ovarian carcinoma: results of five patients. Bone
Marrow Transplant 2002, 30(2):95-102.
243. Rini BI, Zimmerman T, Stadler WM, Gajewski TF, Vogelzang NJ: Allogeneic
stem-cell transplantation of renal cell cancer after nonmyeloablative
chemotherapy: feasibility, engraftment, and clinical results. J Clin Oncol
2002, 20(8):2017-2024.
244. Papadimitriou C, Dafni U, Anagnostopoulos A, Vlachos G, Voulgaris Z,
Rodolakis A, Aravantinos G, Bamias A, Bozas G, Kiosses E, et al: High-dose
melphalan and autologous stem cell transplantation as consolidation
treatment in patients with chemosensitive ovarian cancer: results of a
single-institution randomized trial. Bone Marrow Transplant 2008,
41(6):547-554.
245. Sarosy GA, Reed E: Autologous stem-cell transplantation in ovarian
cancer: is more better? Ann Intern Med 2000, 133(7):555-556.
246. Seidenfeld J, Samson DJ, Bonnell CJ, Ziegler KM, Aronson N: Management
of small cell lung cancer. Evid Rep Technol Assess (Full Rep) 2006, , 143:
1-154.
247. Souhami RL, Hajichristou HT, Miles DW, Earl HM, Harper PG, Ash CM,
Goldstone AH, Spiro SG, Geddes DM, Tobias JS: Intensive chemotherapy
with autologous bone marrow transplantation for small-cell lung cancer.
Cancer Chemother Pharmacol 1989, 24(5):321-325.
248. Humblet Y, Symann M, Bosly A, Delaunois L, Francis C, Machiels J,
Beauduin M, Doyen C, Weynants P, Longueville J, et al: Late intensification
chemotherapy with autologous bone marrow transplantation in selected
small-cell carcinoma of the lung: a randomized study. J Clin Oncol 1987,
5(12):1864-1873.
249. Leyvraz S, Perey L, Rosti G, Lange A, Pampallona S, Peters R, Humblet Y,
Bosquee L, Pasini F, Marangolo M: Multiple courses of high-dose
ifosfamide, carboplatin, and etoposide with peripheral-blood progenitor
cells and filgrastim for small-cell lung cancer: A feasibility study by the
European Group for Blood and Marrow Transplantation. J Clin Oncol
1999, 17(11):3531-3539.
250. Brugger W, Fetscher S, Hasse J, Frommhold H, Pressler K, Mertelsmann R,
Engelhardt R, Kanz L: Multimodality treatment including early high-dose
chemotherapy with peripheral blood stem cell transplantation in
limited-disease small cell lung cancer. Semin Oncol 1998, 25(1 Suppl
2):42-48.
251. Hoelzer D, Gokbuget N, Ottmann O, Pui CH, Relling MV, Appelbaum FR, van
Dongen JJ, Szczepanski T: Acute lymphoblastic leukemia. Hematology Am
Soc Hematol Educ Program 2002, 162-192.
252. Stone RM, O’Donnell MR, Sekeres MA: Acute myeloid leukemia.
Hematology Am Soc Hematol Educ Program 2004, 98-117.
253. Shah NP: Medical management of CML. Hematology Am Soc Hematol Educ
Program 2007, 371-375.
254. Quintas-Cardama A, Cortes JE: Chronic myeloid leukemia: diagnosis and
treatment. Mayo Clin Proc 2006, 81(7):973-988.
255. Yee KW, O’Brien SM: Chronic lymphocytic leukemia: diagnosis and
treatment. Mayo Clin Proc 2006, 81(8):1105-1129.
256. Kay NE, Hamblin TJ, Jelinek DF, Dewald GW, Byrd JC, Farag S, Lucas M,
Lin T: Chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ
Program 2002, 193-213.
257. Fagioli F, Zecca M, Locatelli F, Lanino E, Uderzo C, Di Bartolomeo P,
Berger M, Favre C, Rondelli R, Pession A, et al: Allogeneic stem cell
transplantation for children with acute myeloid leukemia in second
complete remission. J Pediatr Hematol Oncol 2008, 30(8):575-583.
258. Frassoni F, Gualandi F, Podesta M, Raiola AM, Ibatici A, Piaggio G,
Sessarego M, Sessarego N, Gobbi M, Sacchi N, et al: Direct intrabone
transplant of unrelated cord-blood cells in acute leukaemia: a phase I/II
study. Lancet Oncol 2008, 9(9):831-839.
259. Ruiz-Arguelles GJ, Gomez-Almaguer D, Morales-Toquero A, Gutierrez-
Aguirre CH, Vela-Ojeda J, Garcia-Ruiz-Esparza MA, Manzano C, Karduss A,
Sumoza A, de-Souza C, et al: The early referral for reduced-intensity stem
cell transplantation in patients with Ph1 (+) chronic myelogenous
leukemia in chronic phase in the imatinib era: results of the Latin
American Cooperative Oncohematology Group (LACOHG) prospective,
multicenter study. Bone Marrow Transplant 2005, 36(12):1043-1047.
260. Oehler VG, Radich JP, Storer B, Blume KG, Chauncey T, Clift R, Snyder DS,
Forman SJ, Flowers ME, Martin P, et al: Randomized trial of allogeneic
related bone marrow transplantation versus peripheral blood stem cell
transplantation for chronic myeloid leukemia. Biol Blood Marrow
Transplant 2005, 11(2):85-92.
261. Ohnishi K, Ino A, Kishimoto Y, Usui N, Shimazaki C, Ohtake S, Taguchi H,
Yagasaki F, Tomonaga M, Hotta T, et al: Multicenter prospective study of
interferon alpha versus allogeneic stem cell transplantation for patients
with new diagnoses of chronic myelogenous leukemia. Int J Hematol
2004, 79(4):345-353.
262. Das M, Saikia TK, Advani SH, Parikh PM, Tawde S: Use of a reduced-
intensity conditioning regimen for allogeneic transplantation in patients
with chronic myeloid leukemia. Bone Marrow Transplant 2003,
32(2):125-129.
263. Mohty M, Labopin M, Tabrizzi R, Theorin N, Fauser AA, Rambaldi A,
Maertens J, Slavin S, Majolino I, Nagler A, et al: Reduced intensity
conditioning allogeneic stem cell transplantation for adult patients with
acute lymphoblastic leukemia: a retrospective study from the European
Group for Blood and Marrow Transplantation. Haematologica 2008,
93(2):303-306.
264. Tobinai K, Takeyama K, Arima F, Aikawa K, Kobayashi T, Hanada S, Kasai M,
Ogura M, Sueoka E, Mukai K, et al: Phase II study of chemotherapy and
stem cell transplantation for adult acute lymphoblastic leukemia or
lymphoblastic lymphoma: Japan Clinical Oncology Group Study 9004.
Cancer Sci 2007, 98(9):1350-1357.
265. Isidori A, Motta MR, Tani M, Terragna C, Zinzani P, Curti A, Rizzi S, Taioli S,
Giudice V, D’Addio A, et al: Positive selection and transplantation of
autologous highly purified CD133(+) stem cells in resistant/relapsed
chronic lymphocytic leukemia patients results in rapid hematopoietic
reconstitution without an adequate leukemic cell purging. Biol Blood
Marrow Transplant 2007, 13(10):1224-1232.
266. Grigg AP, Gibson J, Bardy PG, Reynolds J, Shuttleworth P, Koelmeyer RL,
Szer J, Roberts AW, To LB, Kennedy G, et al: A prospective multicenter trial
of peripheral blood stem cell sibling allografts for acute myeloid
leukemia in first complete remission using fludarabine-
cyclophosphamide reduced intensity conditioning. Biol Blood Marrow
Transplant 2007, 13(5):560-567.
267. Gutierrez-Aguirre CH, Gomez-Almaguer D, Cantu-Rodriguez OG, Gonzalez-
Llano O, Jaime-Perez JC, Herena-Perez S, Manzano CA, Estrada-Gomez R,
Gonzalez-Carrillo ML, Ruiz-Arguelles GJ: Non-myeloablative stem cell
transplantation in patients with relapsed acute lymphoblastic leukemia:
results of a multicenter study. Bone Marrow Transplant 2007, 40(6):535-539.
268. Dreger P, Brand R, Hansz J, Milligan D, Corradini P, Finke J, Deliliers GL,
Martino R, Russell N, Van Biezen A, et al: Treatment-related mortality and
graft-versus-leukemia activity after allogeneic stem cell transplantation
for chronic lymphocytic leukemia using intensity-reduced conditioning.
Leukemia 2003, 17(5):841-848.
269. Marina Cavazzana-Calvo GC, George Q Daley, De Luca Michele, Ira J Fox,
Gerstle Claude, Robert A, Goldstein GH, Katherine A High, Hyun Ok Kim, Hin
Peng Lee, Ephrat Levy-Lahad, Lingsong Li BL, Daniel R Marshak,
Angela McNab, Munsie Megan, Nakauchi Hiromitsu, Mahendra Rao, Carlos
Simon Valles, Srivastava Alok, Sugarman Jeremy, Patrick L Taylor,
Veiga Anna, Zoloth Laurie, Wong AL: Guidelines for the Clinical
Translation of Stem Cells.Edited by: Research ISfSC 2008, 19.
270. Daley GQ: Stem cells: roadmap to the clinic. J Clin Invest 120(1):8-10.
271. Watt FM, Driskell RR: The therapeutic potential of stem cells. Philos Trans R
Soc Lond B Biol Sci 365(1537):155-163.
272. Trounson A: New perspectives in human stem cell therapeutic research.
BMC Med 2009, 7:29.
Lodi et al. Journal of Experimental & Clinical Cancer Research 2011, 30:9
http://www.jeccr.com/content/30/1/9
Page 19 of 20273. Kroon E, Martinson LA, Kadoya K, Bang AG, Kelly OG, Eliazer S, Young H,
Richardson M, Smart NG, Cunningham J, et al: Pancreatic endoderm
derived from human embryonic stem cells generates glucose-responsive
insulin-secreting cells in vivo. Nat Biotechnol 2008, 26(4):443-452.
274. Preynat-Seauve O, Burkhard PR, Villard J, Zingg W, Ginovart N, Feki A,
Dubois-Dauphin M, Hurst SA, Mauron A, Jaconi M, et al: Pluripotent stem
cells as new drugs? The example of Parkinson’s disease. Int J Pharm
2009, 381(2):113-121.
275. Burt RK, Loh Y, Cohen B, Stefoski D, Balabanov R, Katsamakis G, Oyama Y,
Russell EJ, Stern J, Muraro P, et al: Autologous non-myeloablative
haemopoietic stem cell transplantation in relapsing-remitting multiple
sclerosis: a phase I/II study. Lancet Neurol 2009, 8(3):244-253.
276. Crop MJ, Baan CC, Korevaar SS, Ijzermans JN, Alwayn IP, Weimar W,
Hoogduijn MJ: Donor-derived mesenchymal stem cells suppress
alloreactivity of kidney transplant patients. Transplantation 2009,
87(6):896-906.
277. Troeger A, Meisel R, Moritz T, Dilloo D: Immunotherapy in allogeneic
hematopoietic stem cell transplantation–not just a case for effector
cells. Bone Marrow Transplant 2005, 35(Suppl 1):S59-64.
278. Le Blanc K, Frassoni F, Ball L, Locatelli F, Roelofs H, Lewis I, Lanino E,
Sundberg B, Bernardo ME, Remberger M, et al: Mesenchymal stem cells for
treatment of steroid-resistant, severe, acute graft-versus-host disease: a
phase II study. Lancet 2008, 371(9624):1579-1586.
279. Iyer SS, Co C, Rojas M: Mesenchymal stem cells and inflammatory lung
diseases. Panminerva Med 2009, 51(1):5-16.
280. Nasef A, Ashammakhi N, Fouillard L: Immunomodulatory effect of
mesenchymal stromal cells: possible mechanisms. Regen Med 2008,
3(4):531-546.
281. Yamanaka S: A fresh look at iPS cells. Cell 2009, 137(1):13-17.
282. Zhou H, Wu S, Joo JY, Zhu S, Han DW, Lin T, Trauger S, Bien G, Yao S,
Zhu Y, et al: Generation of induced pluripotent stem cells using
recombinant proteins. Cell Stem Cell 2009, 4(5):381-384.
283. Yamashita JK: ES and iPS cell research for cardiovascular regeneration.
Exp Cell Res 2010, 316(16):2555-2559.
284. Foster KW, Liu Z, Nail CD, Li X, Fitzgerald TJ, Bailey SK, Frost AR, Louro ID,
Townes TM, Paterson AJ, et al: Induction of KLF4 in basal keratinocytes
blocks the proliferation-differentiation switch and initiates squamous
epithelial dysplasia. Oncogene 2005, 24(9):1491-1500.
285. Hochedlinger K, Yamada Y, Beard C, Jaenisch R: Ectopic expression of Oct-
4 blocks progenitor-cell differentiation and causes dysplasia in epithelial
tissues. Cell 2005, 121(3):465-477.
286. Nair V: Retrovirus-induced oncogenesis and safety of retroviral vectors.
Curr Opin Mol Ther 2008, 10(5):431-438.
287. Soldner F, Hockemeyer D, Beard C, Gao Q, Bell GW, Cook EG, Hargus G,
Blak A, Cooper O, Mitalipova M, et al: Parkinson’s disease patient-derived
induced pluripotent stem cells free of viral reprogramming factors. Cell
2009, 136(5):964-977.
288. Maherali N, Hochedlinger K: Guidelines and techniques for the generation
of induced pluripotent stem cells. Cell Stem Cell 2008, 3(6):595-605.
289. Tenzen T, Zembowicz F, Cowan CA: Genome modification in human
embryonic stem cells. J Cell Physiol 2010, 222(2):278-281.
290. Zarzeczny A, Scott C, Hyun I, Bennett J, Chandler J, Charge S, Heine H,
Isasi R, Kato K, Lovell-Badge R, et al: iPS cells: mapping the policy issues.
Cell 2009, 139(6):1032-1037.
291. Lewis R, Zhdanov RI: Centenarians as stem cell donors. Am J Bioeth 2009,
9(11):1-3.
doi:10.1186/1756-9966-30-9
Cite this article as: Lodi et al.: Stem cells in clinical practice: applications
and warnings. Journal of Experimental & Clinical Cancer Research 2011 30:9.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Lodi et al. Journal of Experimental & Clinical Cancer Research 2011, 30:9
http://www.jeccr.com/content/30/1/9
Page 20 of 20